<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9998920</article-id><article-id pub-id-type="pmcid-ver">PMC9998920.1</article-id><article-id pub-id-type="pmcaid">9998920</article-id><article-id pub-id-type="pmcaiid">9998920</article-id><article-id pub-id-type="pmid">36911719</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1043109</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>New-age vaccine adjuvants, their development, and future perspective</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Verma</surname><given-names initials="SK">Shailendra Kumar</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/317715"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahajan</surname><given-names initials="P">Pooja</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singh</surname><given-names initials="NK">Nikhlesh K.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="A">Ankit</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/992743"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names initials="R">Rupesh</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names initials="R">Rino</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/421853"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Johri</surname><given-names initials="AK">Atul Kumar</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/220575"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>School of Biotechnology, Jawaharlal Nehru University</institution>, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>School of Life Sciences, Jawaharlal Nehru University</institution>, <addr-line>New Delhi</addr-line>, <country>India</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Integrative Biosciences Center, Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, School of Medicine</institution>, <addr-line>Detroit, MI</addr-line>, <country>United States</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Microbiology Division, Defence Research and Development Establishment</institution>, <addr-line>Gwalior</addr-line>, <country>India</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Glaxo Smith Kline (GSK) Vaccine</institution>, <addr-line>Siena</addr-line>, <country>Italy</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Denise L. Doolan, James Cook University, Australia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Yongjun Sui, National Cancer Institute (NIH), United States; Slim Fourati, Emory University, United States</p></fn><corresp id="fn001">*Correspondence: Atul Kumar Johri, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:akjohri14@yahoo.com">akjohri14@yahoo.com</email>; Shailendra Kumar Verma, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:skverma@lji.org">skverma@lji.org</email></corresp><fn fn-type="present-address" id="fn003"><p>&#8224;Present Addresses: Shailendra Kumar Verma, Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States; Rino Rappuoli, Fondazione Biotecnopolo di Siena, Siena, Italy</p></fn><fn fn-type="other" id="fn002"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427662</issue-id><elocation-id>1043109</elocation-id><history><date date-type="received"><day>13</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>11</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-05 11:25:21.567"><day>05</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Verma, Mahajan, Singh, Gupta, Aggarwal, Rappuoli and Johri</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Verma, Mahajan, Singh, Gupta, Aggarwal, Rappuoli and Johri</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-14-1043109.pdf"/><abstract><p>In the present scenario, immunization is of utmost importance as it keeps us safe and protects us from infectious agents. Despite the great success in the field of vaccinology, there is a need to not only develop safe and ideal vaccines to fight deadly infections but also improve the quality of existing vaccines in terms of partial or inconsistent protection. Generally, subunit vaccines are known to be safe in nature, but they are mostly found to be incapable of generating the optimum immune response. Hence, there is a great possibility of improving the potential of a vaccine in formulation with novel adjuvants, which can effectively impart superior immunity. The vaccine(s) in formulation with novel adjuvants may also be helpful in fighting pathogens of high antigenic diversity. However, due to the limitations of safety and toxicity, very few human-compatible adjuvants have been approved. In this review, we mainly focus on the need for new and improved vaccines; the definition of and the need for adjuvants; the characteristics and mechanisms of human-compatible adjuvants; the current status of vaccine adjuvants, mucosal vaccine adjuvants, and adjuvants in clinical development; and future directions.</p></abstract><kwd-group><kwd>improved vaccines</kwd><kwd>adjuvants</kwd><kwd>mucosal vaccine</kwd><kwd>immune response</kwd><kwd>infectious disease</kwd></kwd-group><funding-group><funding-statement>This work was supported by the University Grants Commission, Government of India, and Israel Science Foundation under grant F. No. 6-5/2016 (1C) to AKJ. This work was supported by the University Grants Commission and Prime Minister Research Fellowship (PMRF), Government of India (to PM and RA, respectively).</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><equation-count count="0"/><ref-count count="216"/><page-count count="17"/><word-count count="8435"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The invention of vaccines has been considered as one of the triumphs of medical research. Immunization not only stops the spread of infection during childhood but also provides a lifetime of protection against some diseases. However, the scientific community continues to face challenges in developing ideal vaccines against many infectious diseases, i.e., plague, tuberculosis, malaria, human immunodeficiency virus (HIV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), due to immunological barriers such as inadequate immune response and weak immunological memory against vaccines (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). Apart from these obstacles, vaccine safety issues such as adverse effects in a population suffering from rare genetic disorders, systemic and local reactogenicity caused by diphtheria and tetanus toxoids along with whole cell pertussis (DTwP), and waning immunity shown by diphtheria and tetanus toxoids along with acellular pertussis (DTaP) (<xref rid="B4" ref-type="bibr">4</xref>) have been considered unacceptable, which further increases the impact of the challenge to solve the vaccine problem for emerging or reemerging disease threats. These challenges warrant new strategies that can help to understand immune responses for immunization and introduce new ways to induce robust immunity without sacrificing quality and safety (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The worldwide scientific community has recently witnessed significant disease outbreaks, i.e., SARS in 2003, the H1N1 influenza pandemic of 2009, Ebola virus in 2014 (<xref rid="B6" ref-type="bibr">6</xref>), the plague in Madagascar in 2017 (<xref rid="B7" ref-type="bibr">7</xref>), the Nipah outbreak in India in 2018 (<xref rid="B8" ref-type="bibr">8</xref>), and, the most notable thus far, the ongoing COVID-19 pandemic (<xref rid="B9" ref-type="bibr">9</xref>). In 2014, the Ebola epidemic created huge panic in developed countries as the mortality rate was found to be quite high in West African countries (<xref rid="B10" ref-type="bibr">10</xref>). These incidences force the scientific community not only to be alert but also to open up new avenues in pursuing new strategies to elucidate the mechanistic approach to develop an effective vaccine against these emerging pathogens (<xref rid="B11" ref-type="bibr">11</xref>). At present, the ongoing COVID-19 pandemic has greatly affected human lives worldwide and devastated the global economy; therefore, the scientific community at large is busy developing an effective and safe vaccine against SARS-CoV-2 (<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Currently, inactivated, live-attenuated, subunit, and nucleic acid-based vaccines are the four types of vaccines available for the human population (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Live-attenuated vaccines comprise the whole pathogen that can replicate in the host body and induce strong immune responses. Live-attenuated vaccines have been observed to be the most effective against polio, Measles, Mumps and Rubella (MMR), chicken pox, influenza, rotavirus, and yellow fever. Killed whole-pathogen vaccines are inactivated by heat or chemicals [inactivated polio (Salk) and hepatitis A], are noninfectious, and are mostly safe. Inactivated (killed) vaccines have been observed to induce weak and short-term immunity, thus the need for boosters to achieve complete protection (<xref rid="B15" ref-type="bibr">15</xref>). It has been found that DTwP from India, which is a kind of licensed inactivated vaccine, bypasses waning immunity and shows long-term protective efficacy (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B16" ref-type="bibr">16</xref>).</p><p>Similar to inactivated whole-pathogen vaccines, purified or recombinant subunit vaccines do not contain live components of the pathogen, but they consist only of the antigenic parts of the pathogen, which makes them different from the former. Subunit vaccine antigens have been poorly immunogenic, hence the need to add components to enhance their protective immunity. Subunit vaccines sometimes use epitopes that are shown to identify and interact with T cells or immunoglobulins. Subunit vaccines have been generally documented safe in terms of toxicity and reactogenicity, as subunit vaccines comprise purified or recombinant antigens rather than the whole cell (<xref rid="B17" ref-type="bibr">17</xref>). There are a few very successful examples of subunit vaccines, such as hepatitis B virus (HBV), influenza virus (injection), and pertussis vaccines. The developed subunit vaccines have been found to be poorly immunogenic, and thus, multiple boosters and suitable adjuvantation are necessary to augment their protective potential. Recently, mRNA vaccines (nucleic acid-based vaccines) have been found to play an important role during the COVID-19 pandemic. These mRNA-based vaccines provide good immune response by directing the production of antibodies, thus preventing serious complications (<xref rid="B18" ref-type="bibr">18</xref>).</p></sec><sec id="s2"><title>The need for adjuvants</title><p>Adjuvants were first discovered in 1920 by Gaston Ramon, a French scientist who observed in his findings that the inclusion of aluminum salts to vaccines enhanced their potential. The term &#8220;adjuvant&#8221; originated from the Latin word <italic toggle="yes">adjuvare</italic>, which means &#8220;to help.&#8221; Adjuvants are generally not immunogenic, but they modulate the immune responses in formulation with the given vaccines, thus not only reducing the required dose of vaccine but also extending immune memory. Typically, the vaccines are formulated with suitable adjuvants to augment the immune responses to the administered vaccine antigen to evaluate the potential to halt the contagion. Another important role of adjuvants is to direct humoral and cell-mediated immune responses to generate pathogen-specific immunity (<xref rid="B19" ref-type="bibr">19</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>).</p><p>At present, adjuvants are exploited (a) to augment the immune response to the given vaccine and enhance the antibody response and the number of recipients that were vaccinated; (b) to enhance rates of seroconversion in individuals with diminished responsiveness due to age, illness, or therapeutic interventions, e.g., the use of the adjuvant MF59 with the influenza vaccine to improve/increase the response in aged individuals (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>); and (c) to reduce the dose and the number of boosters of vaccine antigens (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>) as the ability of an adjuvant to allow comparable responses with considerably lower amounts of vaccine antigen might be crucial in regions where vaccine production facilities are limited and immunization is urgent in public in general. The demand for vaccines with multiple boosters poses noteworthy challenges worldwide. Adjuvants can decrease the number of required boosters to provide complete protection (<xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Schematic representation of vaccine adjuvants and their benefits.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1043109-g001.jpg"/></fig><p>Another reason for formulating a vaccine with an adjuvant is to attain qualitative modulation of the immune response. Adjuvants are used to a greater extent for underdeveloped vaccines to modulate types of immune responses that are not effectively stimulated by vaccine antigens without adjuvants. Adjuvants are used in preclinical and clinical studies (i) to provide functionally suitable immune responses (e.g., humoral or cellular, Th1, Th2, and Th17); furthermore, it has been observed that balanced Th1/Th2/Th17 responses increase the duration of T-cell responses and prolong mouse survival (<xref rid="B29" ref-type="bibr">29</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>); (ii) to enhance long-term memory cells (e.g., T-cell memory) (<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>); (iii) to provide the initial rapid response that can be essential in a pandemic (<xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>); and (iv) to modify the breadth, specificity, or affinity of the response (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). In this review, our main objective is to focus on the modulation of the immune response using various adjuvants.</p></sec><sec id="s3"><title>Characteristics and mechanisms of action</title><sec id="s3_1"><title>Aluminum salts (alum)</title><p>Aluminum salts have been clinically approved, and they are the most widely used adjuvants in human vaccines. These adjuvants are made up of the precipitates of aluminum phosphate and aluminum hydroxide for the adsorption of vaccine antigens. Brenntag Biosector, Chemtrade, and SPI Pharma&#8482; are some of the manufacturers that prepare these formulations. Alhydrogel<sup>&#174;</sup>, Rehydragel&#8482;, and Adju-Phos<sup>&#174;</sup> are tradenames of alum that are available in the market (<xref rid="B41" ref-type="bibr">41</xref>). Aluminum salts as adjuvants have been utilized for more than 80 years in vaccine research and usually stimulate the Th2 type of immune response (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Alum has been approved as a component of licensed human vaccines, i.e., <italic toggle="yes">Haemophilus influenzae</italic> type b (Hib), both hepatitis A and B viruses, tetanus, meningococcal virus, human papilloma virus (HPV), diphtheria, and the most recent SARS-CoV-2 (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B47" ref-type="bibr">47</xref>). The mechanism of action of alum is almost known, and it is now clear that depot formation is not an essential step for the activity of alum as an adjuvant (<xref rid="B48" ref-type="bibr">48</xref>&#8211;<xref rid="B50" ref-type="bibr">50</xref>). Alum as an adjuvant primarily evokes innate immunity (<xref rid="B50" ref-type="bibr">50</xref>&#8211;<xref rid="B52" ref-type="bibr">52</xref>). Alum stimulates B-cell differentiation to augment antibody production (<xref rid="B53" ref-type="bibr">53</xref>). It is also well documented that alum stimulates the Th2 type of immune response in mice, but in humans, almost all the vaccine antigens in formulation with the alum adjuvant induce a mixed type of response, i.e., Th1 and Th2 (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Alum triggers the NLRP3 inflammasome to express interleukin (IL)-1&#946; after <italic toggle="yes">in vitro</italic> priming of macrophages and dendritic cells (DCs) with lipopolysaccharide (LPS) (<xref rid="B56" ref-type="bibr">56</xref>). However, <italic toggle="yes">in vivo</italic>, the adjuvanticity of alum does not support the data (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). It has been observed that alum stimulates the Th2 type of immune response and produces IL-4, IL-5, IgG1, and IgE (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B57" ref-type="bibr">57</xref>). Another functional activity performed by alum is the initiation of a signaling cascade by using DCs to carry out actin-mediated phagocytosis that leads to the activation of two kinase proteins (Src and Syk), which, in turn, mobilizes Ca<sup>2+</sup> and finally activates the transcription factor NFAT (calcineurin-nuclear factor of activated T cells), resulting in the production of IL-2 (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B58" ref-type="bibr">58</xref>&#8211;<xref rid="B60" ref-type="bibr">60</xref>). In addition, alum mediates its adjuvanticity by activating the cascade of complement proteins (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B61" ref-type="bibr">61</xref>&#8211;<xref rid="B63" ref-type="bibr">63</xref>). Alum as an adjuvant is highly advantageous due to its safety, vaccine antigen stabilization, and the modulation of high-production and long-lasting antibody titers. Vaccines that have been formulated with an alum adjuvant cannot be filter sterilized, lyophilized, or frozen (<xref rid="B64" ref-type="bibr">64</xref>).</p></sec><sec id="s3_2"><title>Adjuvants in emulsion forms (oil-in-water)</title><sec id="s3_2_1"><title>MF59 and AS03 adjuvants</title><p>MF59 is a highly safe and effective oil-in-water emulsion of squalene oil. Unlike Freund&#8217;s adjuvants, squalene is more readily metabolized and highly purified for vaccine development. Recently, MF59 has been licensed by Fluad&#8482; (Seqirus, Melbourne, Australia) as an important component of flu vaccine for old people, and it has also been successfully used in infants and children later on (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>). Apart from this, it was also licensed to be used as a pandemic vaccine against H1N1 in children, infants, and pregnant women (<xref rid="B67" ref-type="bibr">67</xref>). It is evident from the findings that the MF59 adjuvant trivalent inactivated influenza vaccine (TIV) elicited a strong humoral and cellular immune response in infants in comparison to non-MF59 adjuvanted influenza vaccines (<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B69" ref-type="bibr">69</xref>). The formulation of MF59 significantly modulated the weak efficacy of the influenza vaccine in infants. Subsequently, the HBV vaccine in formulation with the MF59 adjuvant was observed to induce a 100 times stronger immune response in comparison to alum (<xref rid="B70" ref-type="bibr">70</xref>). Similar to other adjuvants, the mechanism of action of MF59 is not yet fully elucidated. The effectiveness of the MF59 adjuvant does not depend on the formation of a depot at the site of vaccination because of the short half-life of MF59 (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B71" ref-type="bibr">71</xref>). However, the MF59 adjuvant has shown the potential to elicit a strong IgG and cell-mediated immune response (<xref rid="B72" ref-type="bibr">72</xref>). Moreover, MF59 can induce monocytes, macrophages, and DCs to express and secrete chemokines, i.e., CCL4, CCL2, CCL5, and CXCL8, which recruit more leukocytes for the reuptake of more vaccine antigens. Finally, this differentiation converts immune cells into antigen-presenting cells (APCs). Furthermore, these APCs migrate to lymph nodes where they induce an adaptive immune response as shown in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref> (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>).</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>MF59 adjuvant and its mechanism of action. At the injection site, MF59 adjuvant-activated macrophages secrete the chemokines that stimulate and recruit the immune cells. Differentiation converts immune cells into antigen-presenting cells to activate B and T cells to impart strong humoral and cellular immune responses.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1043109-g002.jpg"/></fig><p>AS03 is also an oil-in-water emulsion adjuvant that includes squalene, &#945;-tocopherol, and polysorbate 80 (<xref rid="B75" ref-type="bibr">75</xref>). The inclusion of &#945;-tocopherol into the AS03 formulation made it different from other oil-in-water emulsion adjuvants (<xref rid="B76" ref-type="bibr">76</xref>). AS03 was first used in formulation with a vaccine against malaria (<xref rid="B77" ref-type="bibr">77</xref>). Recently, this adjuvant has been used for human vaccination against influenza. Recent clinical trials have shown that the AS03 adjuvant with the influenza vaccine elicited a strong immune response (<xref rid="B78" ref-type="bibr">78</xref>). In addition, the AS03 adjuvant vaccine was found to induce a robust immune response in infants as well (<xref rid="B79" ref-type="bibr">79</xref>). Furthermore, AS03 evokes immunity by stimulating Nuclear factor kappa B (NF-&#954;B), a proinflammatory cytokine, and chemokines. Later, it recruits immune cells such as monocytes and macrophages. The advantage of applying this adjuvant in formulation with the pandemic vaccine is its capability of generating a strong humoral immune response with a lower dose of vaccine antigen, i.e., 3.75 or 7.5 &#956;g per strain in comparison to 15 &#181;g per strain in conventional trivalent inactivated influenza vaccines. Since 2009, ~4.7 million doses of AS03-adjuvanted A(H1N1) vaccines have been injected in children (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>).</p></sec><sec id="s3_2_2"><title>Army liposome formulation</title><p>This formulation was developed by the U.S. military, made up of cholesterol and liposomes containing saturated phospholipids and monophosphoryl lipid A (MPLA) (<xref rid="B82" ref-type="bibr">82</xref>). There are improved versions of army liposome formulation (ALF), i.e., ALF adsorbed to aluminum hydroxide (ALFA), ALF containing the QS21 saponin (ALFQ), and ALFQ adsorbed to aluminum hydroxide (ALFQA) (<xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). It has been found that the vaccine candidate circumsporozite protein of <italic toggle="yes">Plasmodium falciparum</italic> adjuvanted with ALFA imparted adequate humoral and cellular immune responses (<xref rid="B85" ref-type="bibr">85</xref>). The WRAIR (Walter Reed Army Institute of Research) malaria vaccine branch developed and tested the protective efficacy of FMP013 (falciparum malaria protein-013) and FMP014 (a self-assembling protein nanoparticle) SAPN (two new synthetic malarial antigens) with an ALFQ adjuvant (<xref rid="B86" ref-type="bibr">86</xref>&#8211;<xref rid="B88" ref-type="bibr">88</xref>).</p><p>Recombinant gp120 adjuvanted with ALFA induced cross-reactive antibodies against different subtypes of HIV-1 (<xref rid="B89" ref-type="bibr">89</xref>). As regards ALF and ALFQ in formulation with the recombinant HIV-1 envelope gp140 protein, ALF induces a dominant Th2 type of immune response, while ALFQ induces a more balanced Th1 and Th2 type of immunity (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>). In addition, the ALFQ adjuvant activates innate immune responses, upregulates APOBEC3 (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like family), an anti-HIV protein, and maintains a proinflammatory environment, as a result of which, MDMs (monocyte-derived macrophages) that are permissive to HIV-1 infection become capable of restricting HIV-1 infection (<xref rid="B92" ref-type="bibr">92</xref>).</p></sec><sec id="s3_2_3"><title>Virosomes (lipids and glycoproteins)</title><p>Virosomes display the attributes of an adjuvant system and are known for their biodegradable and nontoxic qualities. Generally, virosomes do not generate anti-virosome antibodies (<xref rid="B93" ref-type="bibr">93</xref>). Virosomes are small spherical unilamellar lipid membrane vesicles (150 nm) embedded with viral envelope proteins, such as neuraminidase and hemagglutinin of the influenza virus. These proteins are integrated into phosphatidylcholine bilayer liposomes. These prepared virosomes are devoid of nucleocapsid including the genetic material of the source virus (<xref rid="B94" ref-type="bibr">94</xref>). These proteins facilitate virosome membranes to bind with cell receptors, mediating pH-dependent fusion with immune cells. Consequently, virosomes transport their contents, i.e., vaccine antigen(s), directly to their target cells, evoking an antigen-specific immune response yet carrying a weak immunogenic antigen (<xref rid="B95" ref-type="bibr">95</xref>). Virosomes are virus-like particles that allow the presentation of vaccine antigen to both major histocompatibility complex (MHC) class I and class II to elicit both B-cell and T-cell immune responses (<xref rid="B95" ref-type="bibr">95</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>).</p><p>The types of immune response evoked by the virosome adjuvant system depend on whether the antigenic epitopes are outside or inside the virosome. There are few established examples such as PeviPRO&#8482;, which induces a humoral immune response (<xref rid="B27" ref-type="bibr">27</xref>). The antigen is degraded in endosomes of the cell and, hence, mainly generates an MHC II antigen presentation. PeviTER&#8482; formulated antigens not only elicit a CD4+ and CD8+ T-cell immune response but also generate a strong cytotoxic T lymphocyte (CTL) response. Virosome adjuvant system encapsulation presents vaccine antigens <italic toggle="yes">via</italic> the MHC I route because the antigen is delivered naturally into the APC cytosol (<xref rid="B95" ref-type="bibr">95</xref>). The approved vaccines such as Epaxal<sup>&#174;</sup> (for hepatitis A) and Inflexal<sup>&#174;</sup>V (for influenza) (<xref rid="B100" ref-type="bibr">100</xref>) have successfully proven the excellence of virosomes. Thus far, these hepatitis A (Epaxal<sup>&#174;</sup>) and influenza (Inflexal<sup>&#174;</sup>V) vaccines have been authorized to be used in more than 45 countries, and more than 10 million people have been immunized to date. This new generation of vaccines offers additional benefits because they are effective even in immunosuppressed patients and in infants (<xref rid="B101" ref-type="bibr">101</xref>). Furthermore, they have a high safety profile as embedded viruses do not replicate. To the best of our knowledge, virosomes are no longer licensed to be used in humans.</p></sec><sec id="s3_2_4"><title>AS04 (alum-adsorbed TLR-4 agonist)</title><p>To develop the novel adjuvant systems, aluminum salts have been used, mainly consisting of different Toll-like receptor (TLR) agonists absorbed on alum. Adjuvant system 04 (AS04) has already been approved for use in formulation with HPV (Cervarix) and HBV (Fendrix) vaccines. This adjuvant system includes alum in formulation with LPS that mainly constitutes 3-O-desacyl-4&#8242;-monophosphoryl lipid A (MPLA) from <italic toggle="yes">Salmonella minnesota.</italic> It is documented that MPLA retains the ability to stimulate innate immunity by interaction with TLR-4 (<xref rid="B54" ref-type="bibr">54</xref>). It further leads to induce NF-&#954;B signaling and produce pro-inflammatory cytokines and chemokines that recruit the immune cells at the vaccination site and draining lymph nodes. An increase in the number of monocytes and DCs has been observed within a few hours of vaccination where they interact to stimulate antigen-specific T and B cells for strong cellular and humoral immune responses. There is no synergistic effect shown by alum with MPLA; however, a comparative study of MPLA and AS04 revealed that alum extends the cellular responses evoked by MPLA at the vaccination site. Hence, research findings suggest that the AS04 adjuvant induces innate immune responses by stimulating TLR-4 (<xref rid="B54" ref-type="bibr">54</xref>). The AS04-adjuvanted HBV vaccine elicits innate immune responses in humans (<xref rid="B102" ref-type="bibr">102</xref>). An elevated level of IL-6 and C-reactive protein was observed in the AS04-adjuvanted HBV immunized serum in comparison to the alum-adjuvanted HBV immunized serum. Yet, higher HBs Ag-specific T cells and antibodies were reported than those induced by the HBV vaccine in formulation with alum (<xref rid="B103" ref-type="bibr">103</xref>). Both HBV and HPV vaccines in formulation with AS04 elicit stronger humoral immune responses in comparison to the same vaccines when formulated with the alum adjuvant, signifying the importance of the TLR4 agonist MPLA adjuvant for human use (<xref rid="B103" ref-type="bibr">103</xref>&#8211;<xref rid="B105" ref-type="bibr">105</xref>).</p></sec><sec id="s3_2_5"><title>RC-529 adjuvant</title><p>Sequential acid and base hydrolysis of LPS generates an MPLA that is known to retain various immunostimulatory functions of LPS. <italic toggle="yes">In vitro</italic> studies have shown that MPLA activates and stimulates the maturation of DCs and upregulates the human leukocyte antigen&#8208;DR, CD80, CD86, CD40, and CD83 (<xref rid="B106" ref-type="bibr">106</xref>). MPLA is also known to induce the expression of Th1 and Th2 cytokines (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>) and augment the antigen-specific Tc cell response (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>). MPLA is an approved adjuvant and has been used in hepatitis B vaccine formulations. After this, synthetic mimetics such as aminoalkylglucosaminide 4-phosphates (AGPs) were characterized, and it was observed that they activate innate cells such as macrophages, DCs, B cells, and APCs. One such AGP compound, RC-529, was observed to activate the signal <italic toggle="yes">via</italic> TLR-4 and upregulate the costimulatory molecules on the cell surface including cytokines and chemokines (<xref rid="B107" ref-type="bibr">107</xref>). RC-529 was found to be an effective adjuvant in a clinical trial in which healthy volunteers were administered with a vaccine formulation against hepatitis B. In comparison to alum, RC-529 induced a significantly high production of antibodies in subjects who were administered with the vaccine formulation (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B110" ref-type="bibr">110</xref>). MPLA&#8217;s synthetic mimetic RC-529 was observed as safe and effective in clinical trials (<xref rid="B111" ref-type="bibr">111</xref>).</p></sec></sec></sec><sec id="s4"><title>Mucosal vaccine adjuvants</title><p>These adjuvants evoke the innate immune system of the host and help to provide protection against pathogens. Whole-cell-based vaccines using live-attenuated or killed pathogens usually consist of endogenous adjuvants, such as the products of the bacterial cell wall and their genomic DNA/RNA. These adjuvants act as pathogen-associated molecular patterns (PAMPs) and are adequate to stimulate adaptive immunity. However, subunit vaccines usually miss, or are unable to induce, an innate immune response, and thus, the inclusion of an adjuvant is essential to deliver successful vaccines (<xref rid="B112" ref-type="bibr">112</xref>). Most of the pathogens enter the host <italic toggle="yes">via</italic> either the intranasal or the oral route. Therefore, an effective mucosal vaccine is of utmost importance to prevent such kinds of mucosal transmitted diseases. The mucosal vaccine, in comparison to the intramuscular/subunit vaccine, provides noteworthy benefits such as low cost, noninvasiveness, and, most importantly, very low risk of transmission of blood-borne infections, especially to young children. However, due to the lack of ideal mucosal adjuvants, only a few mucosal vaccines are approved for human use (<xref rid="B113" ref-type="bibr">113</xref>).</p><p>Generally, mucosal adjuvants have two roles: first, they act as delivery vehicles, and second, they act as immunostimulatory molecules. However, some mucosal adjuvants exhibit the characteristics of both immunostimulators and delivery systems, such as chitosan and its derivatives (<xref rid="B114" ref-type="bibr">114</xref>). It is documented that mucosal adjuvants can stimulate protective local and systemic immunity that is crucial for successful mucosal immunizations against various infectious diseases (<xref rid="B115" ref-type="bibr">115</xref>&#8211;<xref rid="B118" ref-type="bibr">118</xref>). In addition, mucosal adjuvants perform many vital roles to provide protection against infections at distant as well as local sites. For example, Cytosine-phosphorothioate-guanine (CpG) oligodeoxynucleotides act as effective mucosal adjuvants for vaccinations <italic toggle="yes">via</italic> the nasal route against pathogens transmitted by blood transfusion and sexual activities (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). Moreover, mucosal adjuvants are strong stimulators of immunity against tumors (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Among many mucosal adjuvants, the agonists of TLR and mutant enterotoxins are the two most appealing types because they are not only effective but also comparatively safe (<xref rid="B115" ref-type="bibr">115</xref>). So far, bacterially derived Adenosine diphosphate (ADP)-ribosylating enterotoxins are the most characterized mucosal adjuvants. This class of adjuvant comprises <italic toggle="yes">Escherichia coli</italic> heat-labile enterotoxin (LT), cholera toxin (CT), and mutants/subunits of LT and CT. These toxins stimulate an antigen-specific cellular and humoral immune response that includes CTLs, Th1, Th2, and Th17. Most importantly, these adjuvants stimulate antigen-specific IgA antibodies and long-lasting memory cells to vaccine antigens when administered <italic toggle="yes">via</italic> the mucosal route (<xref rid="B123" ref-type="bibr">123</xref>).</p></sec><sec id="s5"><title>How do heat-labile toxin/double-mutant heat-labile toxin mucosal adjuvants work?</title><p>The mucosal adjuvant LT is a polymeric protein of 84 kDa. This adjuvant retains an active form as AB5 that contains an A subunit and a pentameric B subunit. dmLT is a mutated form of its parent molecule LT (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>). The adjuvant dmLT immunomodulates the systemic as well as mucosal immune responses specific to the vaccine antigen after vaccination <italic toggle="yes">via</italic> the mucosal or parental route. It can simply be formulated with vaccine antigen(s) in an aqueous buffer. Due to the dual approach of the adjuvant, i.e., immunostimulatory characteristics and universal cell binding, the cell uptake of vaccine antigen(s) are many-fold high, and that is how the mucosal immunity is enhanced. This is the most suitable approach to deliver vaccine formulations, particularly for subunit vaccines to unapproachable sites, and specifically for sublingual (s.l.), oral (p.o.), and transcutaneous (t.c.i.) delivery. These strategies not only are needle-free but also reveal the capacity to enhance ease of administration and compliance. Moreover, it reduces the risk of transmission of the diseases from vaccinations using risky injections (<xref rid="B126" ref-type="bibr">126</xref>&#8211;<xref rid="B129" ref-type="bibr">129</xref>). The dmLT adjuvant evokes a strong Th17 response specific to the vaccine antigen and induces IL-17, and it provides protection against infections mainly in mucosal sites (<xref rid="B130" ref-type="bibr">130</xref>). The expression of IL-17 helps to increase the transport of secretory sIgA antibodies into the lumen of mucosal tissue by inducing B-cell differentiation into IgA-secreting cells (<xref rid="B131" ref-type="bibr">131</xref>&#8211;<xref rid="B134" ref-type="bibr">134</xref>). The dmLT adjuvant also stimulates the mucosal immune responses after parenteral vaccination (<xref rid="B135" ref-type="bibr">135</xref>&#8211;<xref rid="B139" ref-type="bibr">139</xref>). However, these studies have been tested only in animal models, and the use of this adjuvant in humans is yet to be determined.</p><p>LT, CT, and their related mutants have been very well characterized in the recent past (<xref rid="B139" ref-type="bibr">139</xref>&#8211;<xref rid="B141" ref-type="bibr">141</xref>). The subunits of the active form AB5 of LT or CT adjuvant function uniquely. Subunit B binds to the receptor and leads the entry into the cell. During mucosal vaccination, the B subunit helps in transporting the vaccine antigens throughout the mucosal sites (<xref rid="B142" ref-type="bibr">142</xref>). Subunit A is responsible for binding to ADP-ribosylation factors (ARFs), and ADP ribosylates Gs&#945;, which results in an accumulation of Cyclic adenosine monophosphate (cAMP). Then, LT stimulates the activation of DCs, the expression of cytokines, and the stimulation of Th17 response (<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B143" ref-type="bibr">143</xref>). It is also documented that the use of subunit A of LT alone evokes a mixed Th1/Th2/Th17 type of immune response but has a weaker impact than the active AB5 form of LT. The use of subunit B evokes a Th2/T regulatory cell (Treg)-skewed response (<xref rid="B144" ref-type="bibr">144</xref>). However, toxicity has always been a concern for these adjuvants.</p><p>How does the dmLT adjuvant induce the immune system? <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3</bold>
</xref> depicts the immunologic cascade. (I) At the vaccination site, after the uptake of the vaccine antigen, the activation of the innate immune system takes place. The epithelial cells secrete cytokines and chemokines such as IL-8 and granulocyte colony-stimulating factor (G-CSF). (II) The DCs are recruited to the vaccination site and activated for antigen processing and presentation to the major histocompatibility complex (Ag-MHC). The upregulation of CD80 and CD86 and the secretion of polarizing cytokines, e.g., IL-1, IL-23, IL-6, and G-CSF, take place. (III) The activated DCs carrying the vaccine antigen then migrate to the secondary lymphoid organs and facilitate the differentiation of antigen-specific T helper and B cells into plasma cells secreting IgA and IgG antibodies. Finally, a mixed Th1/Th2/Th17 type of immune response is imparted with specifically strong stimulation of Th17 cells (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B145" ref-type="bibr">145</xref>&#8211;<xref rid="B147" ref-type="bibr">147</xref>) and mucosal homing markers (<xref rid="B135" ref-type="bibr">135</xref>). It has been documented that Th17 cells are an essential part of immunity for promoting germinal center formation in secondary lymphoid organs and for augmenting IgA antibody secretion (<xref rid="B132" ref-type="bibr">132</xref>&#8211;<xref rid="B134" ref-type="bibr">134</xref>).</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Mechanism of action of the dmLT adjuvant. (I) At the vaccination site, the dmLT adjuvant stimulates the innate immune response and activated epithelial cells secrete IL-8 and G-CSF. (II) Dendritic cells (DCs) are activated and recruited at the injection site where they process and present the antigen. It also upregulates the costimulatory molecules, i.e., CD80 and CD86, and stimulates the expression of IL-1, IL-6, IL-23, and G-CSF. (III) The activated DCs migrate to secondary lymphoid organs where they stimulate the differentiation of antibody-secreting plasma B cells and the generation of antigen-specific Th cells. Overall, a strong Th17 immune response is imparted. Th17 cells are identified as essential in immunity and in stimulating germinal center formation in secondary lymphoid organs as well as in enhancing IgA secretion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1043109-g003.jpg"/></fig><p>The stimulated DCs by an LT/dmLT adjuvant induced a very high Th17 type of immune response due to the activation of caspase 1 inflammasome and, later, the expression of chemokines and cytokines such as IL-1 and IL-23. A scientific study reported that murine DCs activated with LT induced the expression of IL-1&#946;, which is essential for the production of Th17 cells (<xref rid="B148" ref-type="bibr">148</xref>). Re-stimulation of human Peripheral blood mononuclear cells (PBMC) of immunized individuals with vaccine antigens in formulation with dmLT augmented the expression of IL-17A and IL-13 (<xref rid="B146" ref-type="bibr">146</xref>). In summary, a defined series of events takes place after immunization with a vaccine antigen in formulation with dmLT, which is an effective stimulator of APCs and vaccine immunity (<xref rid="B123" ref-type="bibr">123</xref>).</p></sec><sec id="s6"><title>TLR agonists as a mucosal vaccine adjuvant</title><p>Vaccines in formulation with TLR ligand-based adjuvants trigger and activate an innate immune response that helps in the augmentation of a protective potential imparted by the vaccine candidate. TLR-based adjuvants require an additional adaptor protein, MyD88, which stimulates APCs and B cells for antibody production. In addition, MyD88 signaling also induces germinal center formation that is imperative to produce antibody-secreting cells (<xref rid="B149" ref-type="bibr">149</xref>). TLR ligand-based adjuvants include the TLR9-dependent adjuvant CpG DNA (CpG) and the TLR2-dependent adjuvant Porin B (PorB), both of which require MyD88 for proper stimulation of APCs. CpG is an unmethylated bacterial DNA motif while PorB is an outer-membrane protein of <italic toggle="yes">Neisseria meningitides</italic>. It is documented that TLRs are expressed on APCs, including macrophages, DCs, and B cells. Therefore, the main purpose of using a TLR agonist in vaccine preparation as an adjuvant is to stimulate these cells to impart a robust immune response, linking innate and adaptive immunity (<xref rid="B149" ref-type="bibr">149</xref>). Various ligands for TLR4 have been not only used in preclinical studies but also approved by the Food and Drug Administration for clinical trials like Bacillus Calmette&#8211;Guerin (BCG) and MPLA. LPS, a well-known ligand for TLR4, was used as an inducer of acute inflammation <italic toggle="yes">in vivo</italic> for tumor regression in a mouse model (<xref rid="B150" ref-type="bibr">150</xref>). It has been reported that the TLR4 agonist, a second-generation lipid adjuvant like SLA-SE, promotes an increment in mucosal antibodies elicited by intramuscular immunization with an enterotoxigenic <italic toggle="yes">E. coli</italic> (ETEC) vaccine antigen in a mouse model (<xref rid="B151" ref-type="bibr">151</xref>). To test the efficacy of L-pampo, a combination of TLR1/2 and TLR3 agonists for the SARS-CoV-2 ferret model was utilized, which elicited a vigorous humoral and cell-mediated immune response (<xref rid="B152" ref-type="bibr">152</xref>). More recently, an orally administered SARS-CoV-2 vaccine (VXA-CoV2-1), which is currently in Phase III clinical trial, used the double-stranded RNA adjuvant, which basically targets TLR3 and helps in the activation of the DC population owing to this receptor. The adjuvant used in this study not only broadens the pattern recognition receptor (PRR) target range but also is a promising alternative to toxoid-based adjuvants for oral vaccination (<xref rid="B153" ref-type="bibr">153</xref>). In our opinion, this advancement in adjuvant discovery for mucosal immunity can offer a new hope for combating pathogenic strains and can achieve a successful vaccine design.</p></sec><sec id="s7"><title>The current status of adjuvants and clinical trials</title><p>Safety has always been a great concern in the process of developing novel vaccine adjuvants; therefore, many adjuvants have been comprehensively evaluated in both preclinical and clinical studies. A very commonly used adjuvant, e.g., alum, has been approved in the United States. Alum-adjuvanted vaccines were approved more than 70 years ago. Influenza vaccine in formulation with the emulsion-based vaccine adjuvant MF59 was permitted in 1997 and marketed in Europe. In addition, an emulsion-based vaccine adjuvant such as AS03 was adjuvanted with the influenza vaccine and licensed in 2009. Virosomes, a liposomal adjuvant, were approved in 2000 as an essential part of hepatitis A and influenza vaccines. In addition to this, AS04, a combination adjuvant containing MPLA adsorbed to alum, has been approved in Europe and licensed in the United States. Adjuvants that are licensed for use in humans are listed in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Licensed vaccine adjuvants for human use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Adjuvant name</th><th valign="top" align="center" rowspan="1" colspan="1">Formulation type</th><th valign="top" align="center" rowspan="1" colspan="1">Licensed<break/>(Year)</th><th valign="top" align="center" rowspan="1" colspan="1">Description</th><th valign="top" align="center" rowspan="1" colspan="1">Disease type</th><th valign="top" align="center" rowspan="1" colspan="1">Vaccine Trade Name</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Alum</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Aluminum as mineral salt</td><td valign="top" align="center" rowspan="1" colspan="1">1962</td><td valign="top" align="left" rowspan="1" colspan="1">Insoluble particulates of hydroxide, phosphate, or hydroxyphosphate sulfate salts. Adsorption of antigens by salt; modulates humoral immunity; Th2 type of immune response; increases inflammation</td><td valign="top" align="left" rowspan="1" colspan="1">Diphtheria, tetanus, pertussis, inactivated poliomyelitis vaccine, hepatitis A and B, human papilloma virus, meningococcal, and pneumococcal</td><td valign="top" align="left" rowspan="1" colspan="1">Daptacel, Twinrix, Gardasil, Bexsero, Prevnar 20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>MF59</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oil-in-water emulsion</td><td valign="top" align="center" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">Enhances recruitment of APCs and their activation; promotes antigen uptake and migration of immune cells to lymph nodes; modulates humoral and cellular immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza (both pandemic and seasonal)</td><td valign="top" align="left" rowspan="1" colspan="1">Fluad</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>AS03</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oil-in-water emulsion</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="left" rowspan="1" colspan="1">Induces the production of cytokines and recruitment of immune cells. Modulates humoral and cellular immunity.</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza (pandemic)<break/>Used in influenza vaccine during the 2009 H1N1 pandemic</td><td valign="top" align="left" rowspan="1" colspan="1">aTIV, Pandemrix, and Arepanrix</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Virosome</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Liposome</td><td valign="top" align="center" rowspan="1" colspan="1">2000<break/>These are no longer in use</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes uptake of vaccine antigen by APCs and interacts with B cells leading to T-cell activation. Modulates humoral and cellular immune responses.</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis A and influenza</td><td valign="top" align="left" rowspan="1" colspan="1">Epaxal</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>AS04</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Alum-adsorbed TLR4 agonist</td><td valign="top" align="center" rowspan="1" colspan="1">2005</td><td valign="top" align="left" rowspan="1" colspan="1">Stimulates TLR-4, increasing APC maturation, and imparts the Th1 type of immune responses.<break/>Improves humoral and cellular immune responses.</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus and hepatitis B virus</td><td valign="top" align="left" rowspan="1" colspan="1">Cervarix, Fendrix</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>RC-529</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic TLR4 ligand adsorbed to aluminum hydroxide</td><td valign="top" align="center" rowspan="1" colspan="1">2004</td><td valign="top" align="left" rowspan="1" colspan="1">Induces signal through TLR4, resulting in the upregulation of cell-surface costimulatory molecules and receptors, cytokines, and chemokines</td><td valign="top" align="left" rowspan="1" colspan="1">Licensed product in Argentina for hepatitis B virus</td><td valign="top" align="left" rowspan="1" colspan="1">Supervax</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Imiquimod</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Synthetic TLR7 agonist</td><td valign="top" align="center" rowspan="1" colspan="1">1997</td><td valign="top" align="left" rowspan="1" colspan="1">It activates Langerhans cells, which, in turn, travel to lymph nodes and induce T-cell response</td><td valign="top" align="left" rowspan="1" colspan="1">Genital and perianal warts, actinic keratosis</td><td valign="top" align="left" rowspan="1" colspan="1">Aldara</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Alhydroxiquim-II</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Alum adsorbed to TLR7/8 agonist</td><td valign="top" align="center" rowspan="1" colspan="1">2022</td><td valign="top" align="left" rowspan="1" colspan="1">Small molecules of Alhydroxiquim-II travels to lymph nodes and detaches from alum to activate two cellular receptors TLR7/8</td><td valign="top" align="left" rowspan="1" colspan="1">COVID-19</td><td valign="top" align="left" rowspan="1" colspan="1">COVAXIN</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>CpG ODN (1018 ISS)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Soluble TLR9 ligand (oligonucleotide) co-administered with HBV vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">2012</td><td valign="top" align="left" rowspan="1" colspan="1">Boosts the humoral immune response, Th1-type immunity, CD8+ T-cell-mediated immunity</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B</td><td valign="top" align="left" rowspan="1" colspan="1">Heplisav-B</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>CpG ODN (1018 ISS)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Soluble TLR9 ligand (oligonucleotide) adsorbed to alum</td><td valign="top" align="center" rowspan="1" colspan="1">2022</td><td valign="top" align="left" rowspan="1" colspan="1">Increased cellular and humoral immunity with significant Th1-specific cytokine expression</td><td valign="top" align="left" rowspan="1" colspan="1">COVID-19</td><td valign="top" align="left" rowspan="1" colspan="1">CorbeVax</td></tr></tbody></table></table-wrap><p>Despite offering many noteworthy benefits such as reduced cost, high yield, and better safety of highly purified vaccine antigens, most of these provide a weaker vaccine potential due to the lack of intrinsic immunostimulatory factors like various PAMPs. It is essential to understand how immune cell receptors such as TLRs are stimulated by PAMPs, i.e., LPS of Gram-negative bacteria, and how the adaptive immune response is coordinated and regulated by the innate immune response (<xref rid="B154" ref-type="bibr">154</xref>). It has been reported that particulate material stimulates innate immune signals (<xref rid="B155" ref-type="bibr">155</xref>). Thus, adjuvants were identified for stimulating the specific receptors on innate immune cells that can easily sense danger signals and cellular stress.</p><p>Unfortunately, due to the high reactogenicity and poor tolerance, the early developed adjuvants could not reach clinical development. Because of the characterizations of HIV and malaria vaccines, the rationale that a combination of different adjuvants is a better option to synergistically promote a broad range of immune responses, i.e., humoral and cellular, emerged (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B156" ref-type="bibr">156</xref>, <xref rid="B157" ref-type="bibr">157</xref>). This combination of adjuvants involved a delivery system, i.e., liposomes, alum, or emulsions, as well as a natural immune stimulator immune potentiator such as bacterial MPLA, viral dsRNA, or the plant Quillaja saponins. The new-generation adjuvants are mostly known as immune stimulators or immune potentiators, which have been tested in humans and are under clinical trials listed in <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>. These new-generation adjuvant systems were designed based on existing drug delivery models and established pharmaceutical principles (<xref rid="B170" ref-type="bibr">170</xref>). Thus, the delivery system performed is mainly on immune signal activation that could be localized and focused on the formulated vaccine antigen (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B171" ref-type="bibr">171</xref>&#8211;<xref rid="B174" ref-type="bibr">174</xref>). The adjuvant system (AS) of GSK is the best example of this advancement to make an effective vaccine against malaria (<xref rid="B80" ref-type="bibr">80</xref>). How important is the delivery system for vaccine development? It was mentioned and emphasized in the human clinical trial of two alternative vaccines of GSK. Both vaccines contain the same immune potentiators, but they were formulated differently. The vaccine that contained the AS01 adjuvant system (a liposome formulation) provided better protection in comparison to the vaccine containing the same constituents in the AS02 adjuvant system (an emulsion formulation) (<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B168" ref-type="bibr">168</xref>). Therefore, the vaccine candidate RTS,S was formulated with the adjuvant system AS01, and this example proved that the combination of two immunopotentiators is necessary to achieve the goal. The adjuvant system AS01 contains both MPLA and the saponin QS-21. Studies suggest that when these two immune potentiators (MPLA and QS-21) were formulated in liposomes, they work synergistically and evoke an innate immune response that further augments the adaptive immune response (<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B174" ref-type="bibr">174</xref>&#8211;<xref rid="B176" ref-type="bibr">176</xref>). The capacity of the AS01 adjuvant system to stimulate the robust T-cell immune response in humans for various vaccine antigens is elucidated by the synergistic effect imparted by this unique combination of immunopotentiators, e.g., MPLA and QS-21. These findings open the doors and provide new avenues for the development of potential adjuvant systems (<xref rid="B177" ref-type="bibr">177</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Vaccine adjuvants in the process of development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Adjuvant name</th><th valign="top" align="center" rowspan="1" colspan="1">Formulation type</th><th valign="top" align="center" rowspan="1" colspan="1">Description</th><th valign="top" align="center" rowspan="1" colspan="1">Clinical development stage</th><th valign="top" align="center" rowspan="1" colspan="1">Disease name/vaccine</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>AS01</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes, dispersed lipid vesicles containing TLR4 ligand (MPLA) and saponin QS-21</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the antibody titer, Th1 type of immune response, and CD8+ T-cell-mediated immunity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria, (RTS,S) and for approval for herpes zoster vaccine (HZ/su)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B158" ref-type="bibr">158</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>ALF</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes containing saturated phospholipids, cholesterol, and monophosphoryl lipid A (MPLA)</td><td valign="top" align="left" rowspan="1" colspan="1">Imparts adequate humoral and cellular immune response</td><td valign="top" align="center" rowspan="1" colspan="1">Phase I</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria (FMP013, FMP014), HIV-1 (gp140)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Topical cream with TLR7 ligand</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">A topical cream of TLR7 ligand (imiquimod) applied in conjunction with intradermal immunization</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes the innate immunity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase III</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B159" ref-type="bibr">159</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>EGVac system</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Bacterial polysaccharide/bacterial DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the immune response against HPV <italic toggle="yes">via</italic> both B-cell (humoral) and T-cell (cellular) immune signal stimulation</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B160" ref-type="bibr">160</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Saponin complexes (ISCOM, Matrix-M)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Lipid, purified saponins, and cholesterol cage-like nanocomplexes</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the antibody titer, and Th1 and Th2 type of immune response including CD8+ T-cell-mediated immunity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase I</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B161" ref-type="bibr">161</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>GLA-SE Glucopyranosyl Lipid A (GLA)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oil-in-water nano-emulsion (SE) with synthetic TLR4 ligand</td><td valign="top" align="left" rowspan="1" colspan="1">Multifunctional immunomodulatory activity including the production of inflammatory cytokines, chemokines, DC maturation, and antigen-presenting functions</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Tuberculosis, RSV, and Leishmania</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B162" ref-type="bibr">162</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>IC31</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Cationic peptide complexed with TLR9 ligand (oligonucleotide)</td><td valign="top" align="left" rowspan="1" colspan="1">Modulates a robust H4-specific IFN-g response</td><td valign="top" align="center" rowspan="1" colspan="1">Phase I</td><td valign="top" align="left" rowspan="1" colspan="1">Tuberculosis</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B163" ref-type="bibr">163</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Water-in-oil emulsions (ISA51)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oil dispersed nano-emulsion (mainly squalene) stabilized with non-ionic surfactant</td><td valign="top" align="left" rowspan="1" colspan="1">Augments antibody production and significant Tc cell activity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Included in licensed seasonal influenza</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B164" ref-type="bibr">164</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>VAX2012Q, VAX125</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">TLR5 ligand protein (flagellin) linked to antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the antibody titer including Th1/Th2 type of immunity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B165" ref-type="bibr">165</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Poly I:C (Ampligen, rintatolimod) PIKA</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Double-stranded RNA polymer analogue and TLR3 ligand</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the antibody titer and Th1 type of immune response including CD8+ T-cell-mediated immunity</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza and rabies</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B166" ref-type="bibr">166</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>VCL-HB01 (Vaxfectin)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Cationic liposome (prophylactic and therapeutic, and DNA based)</td><td valign="top" align="left" rowspan="1" colspan="1">Augments T cells and antibodies</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">Genital herpes</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B167" ref-type="bibr">167</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>AS02</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Oil-in-water nano-emulsion with TLR4 ligand (MPLA) and saponin, QS-21</td><td valign="top" align="left" rowspan="1" colspan="1">Augments the antibody titer and Th1 type of immune response</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II (withdrawn)</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria and HIV</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B168" ref-type="bibr">168</xref>)</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Matrix-M</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Protein-based nanoparticle vaccine technology</td><td valign="top" align="left" rowspan="1" colspan="1">High neutralizing antibody titer and also induces a robust T-cell immune response</td><td valign="top" align="center" rowspan="1" colspan="1">Phase II</td><td valign="top" align="left" rowspan="1" colspan="1">COVID-19</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B169" ref-type="bibr">169</xref>)</td></tr></tbody></table></table-wrap><p>The rationale of most of the adjuvants as a candidate or as a licensed vaccine (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B171" ref-type="bibr">171</xref>&#8211;<xref rid="B174" ref-type="bibr">174</xref>, <xref rid="B178" ref-type="bibr">178</xref>&#8211;<xref rid="B187" ref-type="bibr">187</xref>) became clear from the data collected from clinical studies (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B189" ref-type="bibr">189</xref>). Typically, these adjuvants are known to stimulate the innate immune response very quickly and promptly at the immunization site, draining the stimulated immune cells into the lymph nodes, which is essential to augment the pathogen-specific adaptive immunity. The stimulation of PAMP and danger signal pathways, i.e., TLR, caspase-1, and lysosomal destabilization-Syk/Card9, promotes not only the recruitment of effector cells, including T and B cells, but also the recruitment and activation of APCs. It has been proven from many studies by targeted depletion of the activated APCs that this step is very important to induce vaccine antigen-specific T cells effectively. The type of antigen-specific T-cell phenotypes that will be produced will depend on the nature of innate immune signal activation. The secretion of IL-18 by stimulated subcapsular macrophages may promote the development of IFN-&#947;-secreting CD4+ T cells (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B190" ref-type="bibr">190</xref>). Similarly, the secretion of IL-6 or IL-12 by stimulated APCs may also promote the production of a follicular-helper phenotype of T cells (TFH), which promotes the secretion of high-avidity IgG by B cells, for example, influenza immunization (<xref rid="B191" ref-type="bibr">191</xref>). The adjuvant system that contained TLR ligands can modulate the clonal arrangement and quality of the repertoire of antigen-specific T cells by stimulating the expansion of clones of T cells with better TCR affinity (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B192" ref-type="bibr">192</xref>).</p><p>Novavax, Inc. has developed an important adjuvant named matrix-M. It is based on a saponin compound derived from the bark of <italic toggle="yes">Quillaja saponaria</italic> (Soapbark tree). Currently, the matrix-M adjuvant is being used in formulation with the recombinant spike (S) protein against SARS-CoV-2. At present, this vaccine formulation (COVID-19 vaccine) is in Phase I clinical trial. The matrix-M adjuvant not only induces the production of high neutralizing antibody titers but also induces a robust T-cell immune response and imparts high protective efficacy against various strains of coronavirus (<xref rid="B193" ref-type="bibr">193</xref>&#8211;<xref rid="B195" ref-type="bibr">195</xref>). Matrix-M has also been used in other vaccine formulations such as malaria vaccine (R21/Matrix-M), which is currently in Phase IIb, and influenza vaccine, which reached Phase I (<xref rid="B196" ref-type="bibr">196</xref>, <xref rid="B197" ref-type="bibr">197</xref>). It has been observed that saponins such as Q-21 possess adjuvant activity by inducing an OVA-specific CTL response and high antibody titer by activating caspase 1 in subcapsular sinus macrophages (SSMs) in the draining lymph node (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B198" ref-type="bibr">198</xref>, <xref rid="B199" ref-type="bibr">199</xref>), by activating tyrosine-protein kinase SYK through destabilizing lysosome upon endocytosis (<xref rid="B181" ref-type="bibr">181</xref>). In addition, saponins such as matrix-M play a crucial role in the activation of the innate immune system, allow for dose-sparing in vaccine usage, and induce both humoral and cell-mediated immune responses. However, the molecular mechanism of this adjuvant remains to be elucidated. The mechanism of action of this adjuvant can be defined by using a system vaccinology approach (<xref rid="B32" ref-type="bibr">32</xref>).</p><p>At present, the mechanistic approach and the rationale are correlated with the effectiveness and the acceptability of adjuvanted vaccines in humans. This piece of information might be helpful in providing a protocol on how to assess and characterize new adjuvant systems for vis-to-vis comparisons in nonclinical models (<xref rid="B200" ref-type="bibr">200</xref>&#8211;<xref rid="B204" ref-type="bibr">204</xref>) and in the clinic as well (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B103" ref-type="bibr">103</xref>). A recent study has shown that five different adjuvanted vaccines only affect the quantities of CD4+ T cells specific to vaccine antigen but failed to modulate the range of phenotypes of these cells (<xref rid="B103" ref-type="bibr">103</xref>). Hence, it is not always true that adjuvants affect the quality of the immune response for all antigens. In general, vaccine effectiveness is also heavily reliant on the vaccine antigen itself and on what kind of immunity is needed for protection, for example, HIV vaccine studies (<xref rid="B204" ref-type="bibr">204</xref>&#8211;<xref rid="B206" ref-type="bibr">206</xref>).</p></sec><sec id="s8"><title>Use of adjuvants during the COVID-19 pandemic and future perspective</title><p>To date, we have achieved many insights into a new generation of adjuvants in terms of their immunology, and these insights may be quite helpful in providing future avenues to develop novel adjuvanted vaccines by selecting the suitable combination of adjuvants and antigens (<xref rid="B207" ref-type="bibr">207</xref>&#8211;<xref rid="B209" ref-type="bibr">209</xref>). With the advent of omics and system biology, one can easily elucidate the complicated human immune response stimulated by the ideal vaccines. Through these studies, a unique collection of molecular signatures can be compared with newly characterized vaccines (<xref rid="B206" ref-type="bibr">206</xref>, <xref rid="B209" ref-type="bibr">209</xref>, <xref rid="B210" ref-type="bibr">210</xref>). Moreover, compatible animal models can also be developed and advanced for the evaluation of potential adjuvanted vaccines. In addition, in the clinic, most of the molecular analyses are done based on peripheral blood samples and nonhuman primate models (<xref rid="B203" ref-type="bibr">203</xref>), which allows the evaluation of local immune response to immunization and provides the chance for logical validation of already available peripheral blood signatures. For the speedy development of new-generation adjuvants, nonclinical studies always play a crucial role in bridging clinical interpretations.</p><p>Adjuvants consist mostly of natural components. Current technologies are continuously evolving for the development of new adjuvants; soon, there will be important advancements for adjuvants containing synthetic components. While the approved adjuvants will always be considered valuable assets for the future, the key components of many of these adjuvants have been developed from natural resources and could be exchanged by synthetic molecules that possess a similar function. New molecules that have the potential to become more effective activators and agonists are currently characterized. These molecules can be efficiently produced in bulk at a low cost as they can be easily purified and evaluated and less susceptible to their intrinsic biological variability. In addition, the process for the large-scale production of these synthetic molecules may be less susceptible to the many difficulties and challenges of sourcing and extracting natural components. However, before replacing the natural components in existing adjuvants, the concern about safety and protective efficacy should be addressed in clinical trials for the vaccine in formulation with these new adjuvant candidates. As previously discussed, several promising adjuvant candidates have been studied over the past 100 years; however, only a few adjuvants were approved for human use. The complex acylated polysaccharide emulsan produced by a bacterium, <italic toggle="yes">Acinetobacter calcoaceticus</italic>, can be a good candidate due to its amenability to structural tailoring and its emulsification behavior. We found that emulsan activates macrophages and showed significant adjuvant activity as determined by hapten-specific antibody titers. This immune response was characterized by a high immunoglobulin G2a titer, consistent with a Th1 response. The significant immune potentiation demonstrated by this complex polymer establishes emulsan as an exciting new candidate adjuvant. We proposed that by manipulating the emulsan chemical structure, we can explore the physical basis of PRRs and macrophage activation (<xref rid="B211" ref-type="bibr">211</xref>).</p><p>In the last few years, we gained a deep understanding and immense knowledge of innate immune signals that provide new avenues to focus on adjuvant targets with higher potentials, i.e., TLR, stimulator of interferon genes (STING), retinoic acid-inducible gene I (RIG-I), C-type lectin receptors (CLRs), nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing (NLRP), and interferon-inducible protein (AIM2). In addition, some complex exploratory adjuvant concepts have been developed, including multimeric formulations containing many distinct components (<xref rid="B212" ref-type="bibr">212</xref>). Despite having encouraging results in preclinical studies, such adjuvants hardly play any role in ideal prophylactic vaccines, but with the advent of therapeutic vaccines, there may be additional avenues, if bulk production, robustness, reproducibility problems, etc., can be resolved. Despite having a huge advancement in adjuvants, there are some noteworthy limitations such as the incapability to stimulate a strong CTL response in humans. However, to stimulate a broad and diverse immune response, the adjuvants may also be utilized in prime/boost backgrounds with the inclusion of nucleic acids and vectors (<xref rid="B213" ref-type="bibr">213</xref>). Such an attempt has been made to develop an effective vaccine against HIV using the prime/boost technique, and an adjuvanted vaccine antigen is being evaluated as a booster protein after priming with a vector (<xref rid="B214" ref-type="bibr">214</xref>). Therefore, clinical studies are extremely essential to define the best combinations of a heterologous prime/boost setting.</p><p>Several basic problems can be solved by using a better approach to characterizing the newly developed adjuvants, i.e., by elucidating the signaling cascades specific to the innate immunity, which is required to support the potentiality of a specific vaccine. How is the impact of a quick and prompt stimulation specific to vaccine efficacy? Is there any redundancy among the signal pathways of innate immune response? Is it possible to provide a better result through a more specific stimulation? What are the exact temporal and spatial associations between the effectors of innate immunity such as cell&#8211;cell interaction and cytokine signaling, and the adaptive immune effectors such as B and T cells? Are these reactions time-dependent, in which vaccine antigens and adjuvants remain at the vaccination site, and how are the local APCs activated? In human populations, how are the adjuvants&#8217; specific immune responses affected by ecological factors and individual genetic predispositions? What about the influence of several concurrent medications and already diseased individuals on immunization?</p></sec><sec sec-type="conclusion" id="s9"><title>Conclusion</title><p>The ultimate objective of immunization is to provide effective and long-lasting protection against various infectious diseases. Such kind of immune protection can only be achieved by using vaccine formulations carrying suitable adjuvants and antigens. Adjuvants are essential components of vaccine formulations and can modulate the vaccine response. Earlier methods of vaccine formulations focused on a single type of adjuvant, i.e., alum or emulsion. However, the new vaccine formulations need to stimulate the well-defined cellular and humoral immune responses. Therefore, to trigger robust immune responses, such as humoral and cellular immune responses, there is an utmost need for new immune potentiators or immune stimulant adjuvants in vaccine formulations. The mucosal adjuvant dmLT is the outcome of 25 years of research. It has been proven by both preclinical and clinical studies that dmLT is a safe and potent adjuvant that can induce protective immunity in a suitable formulation. There is a need to focus on some unanswered questions for the improvement of the dmLT adjuvant such as safety and stability issues of antigen&#8211;adjuvant combinations. The mechanism of adjuvanticity and the induction of protective immunity imparted by dmLT also warrant further studies. It has been suggested that dmLT can promote both innate and adaptive immune responses in the case of infants. Vaccine preparation with dmLT has been found to be effective against mucosal infections. It has been concluded that dmLT will be useful to overcome hypo-responsiveness to other whole cell- or LPS-based vaccines such as cholera, <italic toggle="yes">Salmonella typhi</italic>, and <italic toggle="yes">Shigella</italic> vaccines in infants in economically less developed countries (<xref rid="B215" ref-type="bibr">215</xref>). We predict that the use of dmLT in vaccine preparations for infants will be highly effective in the future.</p><p>In the recent past, many insights into the area of adjuvant research have been obtained; now, there is a choice to select a suitable adjuvant rather than a classical adjuvant, such as immune potentiators or combinations thereof, to augment vaccine efficacy. Recently, alum, MF59, AS03, CpG, and matrix-M have been licensed and used in vaccine preparations worldwide against COVID-19 (<xref rid="B216" ref-type="bibr">216</xref>). It has been suggested that synthetic gene coding for the spike protein, whether prefusion stabilized or also receptor binding domain only, is used to engineer mammalian cells, baculovirus, or plant cells to produce the recombinant protein that then is purified, combined with adjuvants, and used as vaccine. During vaccine preparations against COVID-19, we have gained industrial and clinical knowledge with protein-based vaccines combined with licensed adjuvants, and we believe that, in the future, vaccine preparation based on these methods will be well tolerated, effective, and available in large quantities. Furthermore, the use of maturation of RNA and viral vectors to create vaccines during the COVID-19 pandemic has opened up new avenues to produce more effective vaccines in the future for emerging infections. Recently completed clinical studies with new adjuvants recommend that a panel of new immune potentiators or immune stimulators be used in vaccine formulations for human use in the future. The accessibility of these new-generation adjuvants in different combinations will enable rational strategies for the development of successful vaccines.</p></sec><sec sec-type="author-contributions" id="s10"><title>Author contributions</title><p>SV, AJ, and RR have initiated and conceptualized this review. MS was written by SV, AJ, PM, and RA. Figures and tables were created by NS, PM, and AG. Revisions were made by RA, PM, AJ, RR and SV. All the authors have designed and recommended the contents and approved the final version.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the School of Biotechnology and School of Life Sciences, Jawaharlal Nehru University, New Delhi, India, for providing the facility necessary to write this manuscript.</p></ack><sec sec-type="COI-statement" id="s12"><title>Conflict of interest</title><p>Author RR is employed by GSK Vaccine, Italy.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s13"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koff</surname><given-names>WC</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>PR</given-names></name><name name-style="western"><surname>Walker</surname><given-names>BD</given-names></name><name name-style="western"><surname>King</surname><given-names>CR</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name><etal/></person-group>. <article-title>Accelerating next- generationvaccine development for global disease prevention</article-title>. <source>Science</source> (<year>2013</year>) <volume>340</volume>:<elocation-id>1232910</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1232910</pub-id><pub-id pub-id-type="pmid">23723240</pub-id><pub-id pub-id-type="pmcid">PMC4026248</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>BD</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name></person-group>. <article-title>Toward an AIDS vaccine</article-title>. <source>Science</source> (<year>2008</year>) <volume>320</volume>:<page-range>760&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1152622</pub-id><pub-id pub-id-type="pmid">18467582</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>. <article-title>Designing tomorrow&#8217;s vaccines</article-title>. <source>N Engl J Med</source> (<year>2013</year>) <volume>68</volume>:<page-range>551&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmra1204186</pub-id><pub-id pub-id-type="pmcid">PMC3612922</pub-id><pub-id pub-id-type="pmid">23388006</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barman</surname><given-names>S</given-names></name><name name-style="western"><surname>Soni</surname><given-names>D</given-names></name><name name-style="western"><surname>Brook</surname><given-names>B</given-names></name><name name-style="western"><surname>Nanishi</surname><given-names>E</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></name></person-group>. <article-title>Precision vaccine development: Cues from natural immunity</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>662218</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.662218</pub-id><pub-id pub-id-type="pmid">35222350</pub-id><pub-id pub-id-type="pmcid">PMC8866702</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Zmolek</surname><given-names>AC</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name></person-group>. <article-title>Beyond antigens and adjuvants: formulating future vaccines</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>:<fpage>799</fpage>&#8211;<lpage>808</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1172/jci81083</pub-id><pub-id pub-id-type="pmid">26928033</pub-id><pub-id pub-id-type="pmcid">PMC4767337</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>EH</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>TF</given-names></name><name name-style="western"><surname>Madoff</surname><given-names>LC</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>MP</given-names></name><name name-style="western"><surname>Sonricker</surname><given-names>AL</given-names></name><name name-style="western"><surname>Keller</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Global capacity for emerging infectious disease detection</article-title>. <source>Proc Natl Acad Sci U.S.A</source> (<year>2010</year>) <volume>107</volume>:<page-range>21701&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1006219107</pub-id><pub-id pub-id-type="pmcid">PMC3003006</pub-id><pub-id pub-id-type="pmid">21115835</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>. (<year>2017</year>).</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></name></person-group>. <article-title>Nipah virus outbreak in India</article-title>. <source>Lancet</source> (<year>2018</year>) <volume>391</volume>:<fpage>2200</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(18)31252-2</pub-id><pub-id pub-id-type="pmid">31876482</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>World Health Organization. Coronavirus disease</collab></person-group>. (<year>2019</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</uri>.</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebola response team</surname><given-names>WHO</given-names></name></person-group>. <article-title>Ebola Virus disease in West Africa&#8211;the first 9 months of the epidemic and forward projections</article-title>. <source>N Engl J Med</source> (<year>2014</year>) <volume>371</volume>:<page-range>1481&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa1411100</pub-id><pub-id pub-id-type="pmcid">PMC4235004</pub-id><pub-id pub-id-type="pmid">25244186</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>MT</given-names></name></person-group>. <article-title>Recent advances of vaccine adjuvants for infectious diseases</article-title>. <source>Immune Netw</source> (<year>2015</year>) <volume>15</volume>(<issue>2</issue>), <page-range>51&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4110/in.2015.15.2.51</pub-id><pub-id pub-id-type="pmcid">PMC4411509</pub-id><pub-id pub-id-type="pmid">25922593</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J</given-names></name></person-group>. <article-title>A strategic approach to COVID-19 vaccine R&amp;D</article-title>. <source>Science</source> (<year>2020</year>) <volume>368</volume>:<page-range>948&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.abc5312</pub-id><pub-id pub-id-type="pmid">32393526</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riese</surname><given-names>P</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K</given-names></name><name name-style="western"><surname>Ebensen</surname><given-names>T</given-names></name><name name-style="western"><surname>Prochnow</surname><given-names>B</given-names></name><name name-style="western"><surname>A Guzm&#225;n</surname><given-names>C</given-names></name></person-group>. <article-title>Vaccine adjuvants: key tools for innovative vaccine design</article-title>. <source>Curr Top Med Chem</source> (<year>2013</year>) <volume>13</volume>:<page-range>2562&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.2174/15680266113136660183</pub-id><pub-id pub-id-type="pmid">24066891</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>KA</given-names></name></person-group>. <article-title>mRNA vaccines for infectious diseases: principles, delivery and clinical translation</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>(<issue>11</issue>):<page-range>817&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id><pub-id pub-id-type="pmid">34433919</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>D</given-names></name></person-group>. <article-title>Active and passive immunity, vaccine types,excipients and licensing</article-title>. <source>Occup. Med (Lond)</source> (<year>2007</year>) <volume>57</volume>:<page-range>552&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/occmed/kqm110</pub-id><pub-id pub-id-type="pmid">18045976</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>The Central Drugs Standard Control Organisation</collab></person-group>. .</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Orr</surname><given-names>MT</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name></person-group>. <article-title>Key roles of adjuvants in modern vaccines</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>:<page-range>1597&#8211;608</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></name><name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>EV</given-names></name><name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></name><name name-style="western"><surname>Prado</surname><given-names>EO</given-names></name></person-group>. <article-title>SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates</article-title>. <source>NPJ Vaccines</source> (<year>2021</year>) <volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>17</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kenney</surname><given-names>RT</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name></person-group>. <article-title>Adjuvants for the future</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><etal/></person-group>, editors. <source>New generation vaccines</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Informa Healthcare USA, Inc</publisher-name> (<year>2010</year>). p. <page-range>250&#8211;62</page-range>.</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Powell</surname><given-names>J</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>RA</given-names></name></person-group>. <article-title>Modulating vaccine responses with innate immunity</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><etal/></person-group>, editors. <source>New generation vaccines</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Informa Healthcare USA, Inc.</publisher-name> (<year>2010</year>). p. <page-range>183&#8211;90</page-range>.</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rapaka</surname><given-names>RR</given-names></name><name name-style="western"><surname>Cross</surname><given-names>AS</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>MA</given-names></name></person-group>. <article-title>Using adjuvants to drive T cell responses for next-generation infectious disease vaccines</article-title>. <source>Vaccines</source> (<year>2021</year>) <volume>9</volume>(<issue>8</issue>):<elocation-id>820</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9080820</pub-id><pub-id pub-id-type="pmid">34451945</pub-id><pub-id pub-id-type="pmcid">PMC8402546</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facciol&#224;</surname><given-names>A</given-names></name><name name-style="western"><surname>Visalli</surname><given-names>G</given-names></name><name name-style="western"><surname>Lagan&#224;</surname><given-names>A</given-names></name><name name-style="western"><surname>Di Pietro</surname><given-names>A</given-names></name></person-group>. <article-title>An overview of vaccine adjuvants: current evidence and future perspectives</article-title>. <source>Vaccines</source> (<year>2022</year>) <volume>10</volume>(<issue>5</issue>):<elocation-id>819</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines10050819</pub-id><pub-id pub-id-type="pmid">35632575</pub-id><pub-id pub-id-type="pmcid">PMC9147349</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podda</surname><given-names>A</given-names></name></person-group>. <article-title>The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine</article-title>. <source>Vaccine</source> (<year>2001</year>) <volume>19</volume>:<page-range>2673&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(00)00499-0</pub-id><pub-id pub-id-type="pmid">11257408</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beran</surname><given-names>J</given-names></name></person-group>. <article-title>Safety and immunogenicity of a new hepatitis b vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients</article-title>. <source>Expert Opin Biol Ther</source> (<year>2008</year>) <volume>8</volume>:<page-range>235&#8211;47</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1517/14712598.8.2.235</pub-id><pub-id pub-id-type="pmid">18194079</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyle</surname><given-names>J</given-names></name><name name-style="western"><surname>Eastman</surname><given-names>D</given-names></name><name name-style="western"><surname>Millar</surname><given-names>C</given-names></name><name name-style="western"><surname>Camuglia</surname><given-names>S</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J</given-names></name><name name-style="western"><surname>Pearse</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<page-range>2541&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.12.018</pub-id><pub-id pub-id-type="pmid">17240491</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banzhoff</surname><given-names>A</given-names></name><name name-style="western"><surname>Gasparini</surname><given-names>R</given-names></name><name name-style="western"><surname>Laghi-Pasini</surname><given-names>F</given-names></name><name name-style="western"><surname>Staniscia</surname><given-names>T</given-names></name><name name-style="western"><surname>Durando</surname><given-names>P</given-names></name><name name-style="western"><surname>Montomoli</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults</article-title>. <source>PloS One</source> (<year>2009</year>) <volume>4</volume>:<elocation-id>e4384</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0004384</pub-id><pub-id pub-id-type="pmid">19197383</pub-id><pub-id pub-id-type="pmcid">PMC2634740</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>TF</given-names></name><name name-style="western"><surname>Horacek</surname><given-names>T</given-names></name><name name-style="western"><surname>Knuf</surname><given-names>M</given-names></name><name name-style="western"><surname>Damman</surname><given-names>HG</given-names></name><name name-style="western"><surname>Roman</surname><given-names>F</given-names></name><name name-style="western"><surname>Dram&#233;</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<page-range>6284&#8211;90</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.040</pub-id><pub-id pub-id-type="pmid">19856521</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halperin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>S</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S</given-names></name><name name-style="western"><surname>Langley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B</given-names></name><name name-style="western"><surname>McCall-Sani</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Comparison of the safety and immunogenicity of hepatitis b virus surface antigen co-administered with an immunostimulatoryphosphorothioate oligonucleotide and alicensed hepatitis b vaccine in healthy young adults</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>20&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.095</pub-id><pub-id pub-id-type="pmid">16198027</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebensen</surname><given-names>T</given-names></name><name name-style="western"><surname>Libanova</surname><given-names>R</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>K</given-names></name><name name-style="western"><surname>Yevsa</surname><given-names>T</given-names></name><name name-style="western"><surname>Morr</surname><given-names>M</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>CA</given-names></name></person-group>. <article-title>Bis-(3&#8242;, 5&#8242;)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>(<issue>32</issue>):<page-range>5210&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.026</pub-id><pub-id pub-id-type="pmid">21619907</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batra</surname><given-names>L</given-names></name><name name-style="western"><surname>Verma</surname><given-names>SK</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>DP</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>N</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>P</given-names></name><name name-style="western"><surname>Pant</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>HSP70 domain II of <italic toggle="yes">Mycobacterium tuberculosis</italic> modulates immune response and protective potential of F1 and LcrV antigens of yersinia pestis in a mouse model</article-title>. <source>PloS Negl Trop Dis</source> (<year>2014</year>) <volume>8</volume>:<elocation-id>e3322</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pntd.0003322</pub-id><pub-id pub-id-type="pmid">25474358</pub-id><pub-id pub-id-type="pmcid">PMC4256173</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="retraction-forward" ext-link-type="pmc" xlink:href="PMC11315322"/></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>EL</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>GY</given-names></name></person-group>. <article-title>A recombinant trivalent fusion protein F1-LcrV-HSP70(II) augments humoral and cellular immune responses and imparts full protection against <italic toggle="yes">Yersinia pestis</italic>
</article-title>. <source>Front Microbiol</source> (<year>2016</year>) <volume>7</volume>, <elocation-id>71053</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2016.01053</pub-id><pub-id pub-id-type="pmcid">PMC4932849</pub-id><pub-id pub-id-type="pmid">27458447</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>BS</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>P</given-names></name><name name-style="western"><surname>O'Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Emerging concepts in the science of vaccine adjuvants</article-title>. <source>Nat Rev Drug Discovery</source> (<year>2021</year>) <volume>20</volume>(<issue>6</issue>):<page-range>454&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41573-021-00163-y</pub-id><pub-id pub-id-type="pmcid">PMC8023785</pub-id><pub-id pub-id-type="pmid">33824489</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>GH</given-names></name><name name-style="western"><surname>Lian</surname><given-names>BS</given-names></name><name name-style="western"><surname>Kawasaki</surname><given-names>T</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T</given-names></name></person-group>. <article-title>Exploration of pattern recognition receptor agonists as candidate adjuvants</article-title>. <source>Front.Cell.Infect. Microbiol</source> (<year>2021</year>) <volume>968</volume>:<elocation-id>745016</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2021.745016</pub-id><pub-id pub-id-type="pmcid">PMC8526852</pub-id><pub-id pub-id-type="pmid">34692565</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandepapeli&#232;re</surname><given-names>P</given-names></name><name name-style="western"><surname>Horsmans</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M</given-names></name><name name-style="western"><surname>Koutsoukos</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Vaccine adjuvant systems containing monophosphoryl lipid a and QS21 induce strong and persistent humoral and T cell responses against hepatitis b surface antigen in healthy adult volunteers</article-title>. <source>Vaccine</source> (<year>2008</year>) <volume>26</volume>:<page-range>1375&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2007.12.038</pub-id><pub-id pub-id-type="pmid">18272264</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>G</given-names></name><name name-style="western"><surname>Medini</surname><given-names>D</given-names></name><name name-style="western"><surname>Borgogni</surname><given-names>E</given-names></name><name name-style="western"><surname>Zedda</surname><given-names>L</given-names></name><name name-style="western"><surname>Bardelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Malzone</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2009</year>) <volume>106</volume>:<page-range>3877&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0813390106</pub-id><pub-id pub-id-type="pmcid">PMC2646626</pub-id><pub-id pub-id-type="pmid">19237568</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>I</given-names></name><name name-style="western"><surname>Roman</surname><given-names>F</given-names></name><name name-style="western"><surname>Forgus</surname><given-names>S</given-names></name><name name-style="western"><surname>Maes</surname><given-names>C</given-names></name><name name-style="western"><surname>De Boever</surname><given-names>F</given-names></name><name name-style="western"><surname>Dram&#233;</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Priming with AS03 a-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<page-range>849&#8211;57</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.017</pub-id><pub-id pub-id-type="pmid">19835828</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huleatt</surname><given-names>JW</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>EB</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Vaccination with recombinant fusion proteins incorporating toll-like receptor ligands inducesrapid cellular and humoral immunity</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<page-range>763&#8211;75</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.013</pub-id><pub-id pub-id-type="pmid">16968658</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>G</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoschler</surname><given-names>K</given-names></name><name name-style="western"><surname>DeVos</surname><given-names>J</given-names></name><name name-style="western"><surname>Praus</surname><given-names>M</given-names></name><name name-style="western"><surname>Bardelli</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory b cells primed by an MF59 adjuvanted prepandemic vaccine</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2009</year>) <volume>106</volume>:<page-range>7962&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0903181106</pub-id><pub-id pub-id-type="pmcid">PMC2674105</pub-id><pub-id pub-id-type="pmid">19416838</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khurana</surname><given-names>S</given-names></name><name name-style="western"><surname>Chearwae</surname><given-names>W</given-names></name><name name-style="western"><surname>Castellino</surname><given-names>F</given-names></name><name name-style="western"><surname>Manischewitz</surname><given-names>J</given-names></name><name name-style="western"><surname>King</surname><given-names>LR</given-names></name><name name-style="western"><surname>Honorkiewicz</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus</article-title>. <source>Sci Transl Med</source> (<year>2010</year>) <volume>2</volume>:<fpage>15ra15</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3000624</pub-id><pub-id pub-id-type="pmid">20371470</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malherbe</surname><given-names>L</given-names></name><name name-style="western"><surname>Mark</surname><given-names>L</given-names></name><name name-style="western"><surname>Fazilleau</surname><given-names>N</given-names></name><name name-style="western"><surname>McHeyzer-Williams</surname><given-names>LJ</given-names></name><name name-style="western"><surname>McHeyzer-Williams</surname><given-names>MG</given-names></name></person-group>. <article-title>Vaccine adjuvants alter TCR-based selection thresholds</article-title>. <source>Immunity</source> (<year>2008</year>) <volume>28</volume>:<fpage>698</fpage>&#8211;<lpage>709</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2008.03.014</pub-id><pub-id pub-id-type="pmid">18450485</pub-id><pub-id pub-id-type="pmcid">PMC2695494</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name></person-group>. <article-title>Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want</article-title>. <source>NPJ Vaccines</source> (<year>2018</year>) <volume>3</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-018-0089-x</pub-id><pub-id pub-id-type="pmid">30323958</pub-id><pub-id pub-id-type="pmcid">PMC6180056</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>JM</given-names></name></person-group>. <article-title>(How) do aluminium adjuvants work</article-title>? <source>Immunol Lett</source> (<year>2006</year>) <volume>102</volume>:<page-range>10&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.imlet.2005.08.002</pub-id><pub-id pub-id-type="pmid">16188325</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindblad</surname><given-names>EB</given-names></name></person-group>. <article-title>Aluminium adjuvants&#8211;in retrospect andprospect</article-title>. <source>Vaccine</source> (<year>2004</year>) <volume>22</volume>:<page-range>3658&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.032</pub-id><pub-id pub-id-type="pmid">15315845</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>EM</given-names></name></person-group>. <article-title>A guide to vaccinology: from basic principles to new developments</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>(<issue>2</issue>):<fpage>83</fpage>&#8211;<lpage>100</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source> (<year>2021</year>) <volume>21</volume>(<issue>6</issue>):<page-range>803&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s1473-3099(20)30987-7</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id><pub-id pub-id-type="pmid">33548194</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>Lancet Infect Dis</source> (<year>2021</year>) <volume>21</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>51</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source> (<year>2021</year>) <volume>21</volume>(<issue>2</issue>):<page-range>181&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id><pub-id pub-id-type="pmid">33217362</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchison</surname><given-names>S</given-names></name><name name-style="western"><surname>Benson</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>VB</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>AH</given-names></name><name name-style="western"><surname>Garside</surname><given-names>P</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>JM</given-names></name></person-group>. <article-title>Antigen depot is not required for alum adjuvanticity</article-title>. <source>FASEB J</source> (<year>2012</year>) <volume>26</volume>:<page-range>1272&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1096/fj.11-184556</pub-id><pub-id pub-id-type="pmcid">PMC3289510</pub-id><pub-id pub-id-type="pmid">22106367</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awate</surname><given-names>S</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>LA</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G</given-names></name></person-group>. <article-title>Mechanisms of action of adjuvants</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4114</volume>:<elocation-id>114</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2013.00114</pub-id><pub-id pub-id-type="pmcid">PMC3655441</pub-id><pub-id pub-id-type="pmid">23720661</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrack</surname><given-names>P</given-names></name><name name-style="western"><surname>McKee</surname><given-names>AS</given-names></name><name name-style="western"><surname>Munks</surname><given-names>MW</given-names></name></person-group>. <article-title>Towards an understanding of the adjuvant action of aluminium</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>:<page-range>287&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri2510</pub-id><pub-id pub-id-type="pmcid">PMC3147301</pub-id><pub-id pub-id-type="pmid">19247370</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambrecht</surname><given-names>BN</given-names></name><name name-style="western"><surname>Kool</surname><given-names>M</given-names></name><name name-style="western"><surname>Willart</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H</given-names></name></person-group>. <article-title>Mechanism of action of clinically approved adjuvants</article-title>. <source>Curr Opin Immunol</source> (<year>2009</year>) <volume>21</volume>:<page-range>23&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.coi.2009.01.004</pub-id><pub-id pub-id-type="pmid">19246182</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Turning the old adjuvant from gel to nanoparticles to amplify CD8+ T cell responses</article-title>. <source>Adv Sci</source> (<year>2018</year>) <volume>5</volume>(<issue>1</issue>):<elocation-id>1700426</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/advs.201700426</pub-id><pub-id pub-id-type="pmcid">PMC5770685</pub-id><pub-id pub-id-type="pmid">29375970</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavin</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hoebe</surname><given-names>K</given-names></name><name name-style="western"><surname>Duong</surname><given-names>B</given-names></name><name name-style="western"><surname>Ota</surname><given-names>T</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C</given-names></name><name name-style="western"><surname>Beutler</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Adjuvant-enhanced antibody responses in the absence of toll-like receptor signalling</article-title>. <source>Science</source> (<year>2006</year>) <volume>314</volume>:<page-range>1936&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.1135299</pub-id><pub-id pub-id-type="pmcid">PMC1868398</pub-id><pub-id pub-id-type="pmid">17185603</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>SL</given-names></name><name name-style="western"><surname>Bisteau</surname><given-names>M</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>:<page-range>6186&#8211;97</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id><pub-id pub-id-type="pmid">19864596</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>SR</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>CD</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>SK</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name></person-group>. <article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title>. <source>Trends Pharmacolsci</source> (<year>2017</year>) <volume>38</volume>(<issue>9</issue>):<page-range>771&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tips.2017.06.002</pub-id><pub-id pub-id-type="pmid">28668223</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Nookala</surname><given-names>S</given-names></name><name name-style="western"><surname>Re</surname><given-names>F</given-names></name></person-group>. <article-title>Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta andIL-18 release</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>:<page-range>5271&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.178.8.5271</pub-id><pub-id pub-id-type="pmid">17404311</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Tomai</surname><given-names>M</given-names></name><name name-style="western"><surname>Gale</surname><given-names>MJ</given-names><suffix>Jr</suffix></name></person-group>. <article-title>New horizons in adjuvants for vaccine development</article-title>. <source>Trends. Immunol</source> (<year>2009</year>) <volume>30</volume>:<fpage>23</fpage>&#8211;<lpage>32</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.it.2008.09.006</pub-id><pub-id pub-id-type="pmid">19059004</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampath</surname><given-names>V</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>G</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Diamant</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jesenak</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives</article-title>. <source>Allergy</source> (<year>2021</year>) <volume>76</volume>(<issue>6</issue>):<page-range>1640&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/all.14840</pub-id><pub-id pub-id-type="pmcid">PMC8251022</pub-id><pub-id pub-id-type="pmid">33811364</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>A</given-names></name><name name-style="western"><surname>Oleszycka</surname><given-names>E</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>FA</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>M</given-names></name><name name-style="western"><surname>Ozasa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The vaccine adjuvant alum inhibits IL-12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL-12 and enhances T h1 and T h17 responses</article-title>. <source>Eur J Immunol</source> (<year>2012</year>) <volume>42</volume>(<issue>10</issue>):<page-range>2709&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.201242372</pub-id><pub-id pub-id-type="pmid">22777876</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khameneh</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ho</surname><given-names>AW</given-names></name><name name-style="western"><surname>Spreafico</surname><given-names>R</given-names></name><name name-style="western"><surname>Derks</surname><given-names>H</given-names></name><name name-style="western"><surname>Quek</surname><given-names>HQ</given-names></name><name name-style="western"><surname>Mortellaro</surname><given-names>A</given-names></name></person-group>. <article-title>The syk&#8211;NFAT&#8211;IL-2 pathway in dendritic cells is required for optimal sterile immunity elicited by alum adjuvants</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>(<issue>1</issue>):<fpage>196</fpage>&#8211;<lpage>204</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1600420</pub-id><pub-id pub-id-type="pmid">27895176</pub-id><pub-id pub-id-type="pmcid">PMC5164880</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batty</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Heise</surname><given-names>MT</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>EM</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>KM</given-names></name></person-group>. <article-title>Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection</article-title>. <source>Adv Drug Del. Rev</source> (<year>2021</year>) <volume>169</volume>:<page-range>168&#8211;89</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.addr.2020.12.006</pub-id><pub-id pub-id-type="pmcid">PMC7733686</pub-id><pub-id pub-id-type="pmid">33316346</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>MC</given-names></name><name name-style="western"><surname>Isenman</surname><given-names>DE</given-names></name></person-group>. <article-title>Regulation of humoral immunity by complement</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>(<issue>2</issue>):<fpage>199</fpage>&#8211;<lpage>207</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.002</pub-id><pub-id pub-id-type="pmid">22921118</pub-id><pub-id pub-id-type="pmcid">PMC5784422</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#252;ven</surname><given-names>E</given-names></name><name name-style="western"><surname>Duus</surname><given-names>K</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>I</given-names></name><name name-style="western"><surname>H&#248;jrup</surname><given-names>P</given-names></name><name name-style="western"><surname>Houen</surname><given-names>G</given-names></name></person-group>. <article-title>Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>(<issue>9</issue>):<elocation-id>e74445</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0074445</pub-id><pub-id pub-id-type="pmid">24040248</pub-id><pub-id pub-id-type="pmcid">PMC3767739</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>RK</given-names></name></person-group>. <article-title>Aluminum compounds as vaccine adjuvants</article-title>. <source>Adv Drug Deliv. Rev</source> (<year>1998</year>) <volume>32</volume>:<page-range>155&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0169-409x(98)00008-8</pub-id><pub-id pub-id-type="pmid">10837642</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A</given-names></name><name name-style="western"><surname>Podda</surname><given-names>A</given-names></name></person-group>. <article-title>MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development</article-title>? <source>Clin Pharm Ther</source> (<year>2007</year>) <volume>82</volume>:<page-range>740&#8211;4</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/sj.clpt.6100402</pub-id><pub-id pub-id-type="pmid">17971820</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesikari</surname><given-names>T</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>M</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Groth</surname><given-names>N</given-names></name><name name-style="western"><surname>Borkowski</surname><given-names>A</given-names></name><name name-style="western"><surname>O'Hagan</surname><given-names>DT</given-names></name><etal/></person-group>. <article-title>Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant</article-title>. <source>Pediatr Infect Dis J</source> (<year>2009</year>) <volume>28</volume>:<page-range>563&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/inf.0b013e31819d6394</pub-id><pub-id pub-id-type="pmid">19561422</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Ott</surname><given-names>GS</given-names></name><name name-style="western"><surname>Nest</surname><given-names>GV</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Giudice</surname><given-names>GD</given-names></name></person-group>. <article-title>The history of MF59 adjuvant: a phoenix that arose from the ashes</article-title>. <source>Expert Rev Vaccines</source> (<year>2013</year>) <volume>12</volume>:<fpage>13</fpage>&#8211;<lpage>30</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1586/erv.12.140</pub-id><pub-id pub-id-type="pmid">23256736</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesikari</surname><given-names>T</given-names></name><name name-style="western"><surname>Knuf</surname><given-names>M</given-names></name><name name-style="western"><surname>Wutzler</surname><given-names>P</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>A</given-names></name><name name-style="western"><surname>Kieninger-Baum</surname><given-names>D</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Oil-in-water emulsion adjuvant with influenza vaccine in young children</article-title>. <source>N Engl J Meds</source> (<year>2011</year>) <volume>365</volume>:<page-range>1406&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa1010331</pub-id><pub-id pub-id-type="pmid">21995388</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>E</given-names></name><name name-style="western"><surname>Kazmin</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>Bosinger</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2016</year>) <volume>113</volume>:<page-range>1853&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1519690113</pub-id><pub-id pub-id-type="pmcid">PMC4763735</pub-id><pub-id pub-id-type="pmid">26755593</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heineman</surname><given-names>TC</given-names></name><name name-style="western"><surname>Clements-Mann</surname><given-names>ML</given-names></name><name name-style="western"><surname>Poland</surname><given-names>GA</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>RM</given-names></name><name name-style="western"><surname>Izu</surname><given-names>AE</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>A randomized, controlled study in adults of the immunogenicity of a novel hepatitis b vaccine containing MF59 adjuvant</article-title>. <source>Vaccine</source> (<year>1999</year>) <volume>17</volume>:<page-range>2769&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(99)00088-2</pub-id><pub-id pub-id-type="pmid">10438046</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupuis</surname><given-names>M</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>DM</given-names></name><name name-style="western"><surname>Ott</surname><given-names>G</given-names></name></person-group>. <article-title>Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice</article-title>. <source>Vaccine</source> (<year>1999</year>) <volume>18</volume>:<page-range>434&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(99)00263-7</pub-id><pub-id pub-id-type="pmid">10519932</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>I</given-names></name><name name-style="western"><surname>Bugarini</surname><given-names>R</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>KG</given-names></name><name name-style="western"><surname>Podda</surname><given-names>A</given-names></name><name name-style="western"><surname>Wood</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zambon</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Crossreactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy</article-title>. <source>J Infect Dis</source> (<year>2005</year>) <volume>191</volume>:<page-range>1210&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1086/428948</pub-id><pub-id pub-id-type="pmid">15776364</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seubert</surname><given-names>A</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A</given-names></name></person-group>. <article-title>The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>:<page-range>5402&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.180.8.5402</pub-id><pub-id pub-id-type="pmid">18390722</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name><name name-style="western"><surname>Caproni</surname><given-names>E</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>JB</given-names></name></person-group>. <article-title>Vaccine adjuvants: Mode of action</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<elocation-id>214</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2013.00214</pub-id><pub-id pub-id-type="pmid">23914187</pub-id><pub-id pub-id-type="pmcid">PMC3728558</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>DW</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group>. <article-title>Development and evaluation of AS03, an adjuvant system containing &#945;-tocopherol and squalene in an oil-in-water emulsion</article-title>. <source>Expert Rev Vaccines</source> (<year>2012</year>) <volume>11</volume>:<page-range>349&#8211;66</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/erv.11.192</pub-id><pub-id pub-id-type="pmid">22380826</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<page-range>2461&#8211;73</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.011</pub-id><pub-id pub-id-type="pmid">21256188</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoute</surname><given-names>JA</given-names></name><name name-style="western"><surname>Slaoui</surname><given-names>M</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>DG</given-names></name><name name-style="western"><surname>Momin</surname><given-names>P</given-names></name><name name-style="western"><surname>Kester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Desmons</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria</article-title>. <source>N Engl J Med</source> (<year>1997</year>) <volume>336</volume>:<fpage>86</fpage>&#8211;<lpage>91</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejm199701093360202</pub-id><pub-id pub-id-type="pmid">8988885</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;ez-Domingo</surname><given-names>J</given-names></name><name name-style="western"><surname>Garc&#233;s-Sanchez</surname><given-names>M</given-names></name><name name-style="western"><surname>Bald&#243;</surname><given-names>JM</given-names></name><name name-style="western"><surname>Planelles</surname><given-names>MV</given-names></name><name name-style="western"><surname>Ubeda</surname><given-names>I</given-names></name><name name-style="western"><surname>JuBert</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Immunogenicity and safety of H5N1 A/vietnam/1194/2004 (clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study</article-title>. <source>Pediatr Infect Dis J</source> (<year>2010</year>) <volume>29</volume>:<page-range>e35&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/INF.0b013e3181daf921</pub-id><pub-id pub-id-type="pmid">20375709</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmona Martinez</surname><given-names>A</given-names></name><name name-style="western"><surname>Salamanca de la Cueva</surname><given-names>I</given-names></name><name name-style="western"><surname>Boutet</surname><given-names>P</given-names></name><name name-style="western"><surname>Vanden Abeele</surname><given-names>C</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I</given-names></name><name name-style="western"><surname>Devaster</surname><given-names>JM</given-names></name></person-group>. <article-title>A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months</article-title>. <source>Hum Vaccin. Immunother</source> (<year>2014</year>) <volume>10</volume>:<page-range>1959&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.28743</pub-id><pub-id pub-id-type="pmcid">PMC4186022</pub-id><pub-id pub-id-type="pmid">25424805</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></name></person-group>. <article-title>Di pasquale from discovery to licensure, the adjuvant system story</article-title>. <source>Hum Vaccin. Immunother</source> (<year>2017</year>) <volume>13</volume>:<fpage>19</fpage>&#8211;<lpage>33</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/21645515.2016.1225635</pub-id><pub-id pub-id-type="pmid">27636098</pub-id><pub-id pub-id-type="pmcid">PMC5287309</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkins</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kazmin</surname><given-names>D</given-names></name><name name-style="western"><surname>Napolitani</surname><given-names>G</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>EA</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B</given-names></name><name name-style="western"><surname>Siegrist</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>AS03- and MF59-adjuvanted influenza vaccines in children</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>13</volume>:<elocation-id>1760</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.01760</pub-id><pub-id pub-id-type="pmcid">PMC5733358</pub-id><pub-id pub-id-type="pmid">29326687</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name><name name-style="western"><surname>Peachman</surname><given-names>KK</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name></person-group>. <article-title>Army liposome formulation (ALF) family of vaccine adjuvants</article-title>. <source>Expert Rev Vaccines</source> (<year>2020</year>) <volume>19</volume>(<issue>3</issue>):<page-range>279&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2020.1745636</pub-id><pub-id pub-id-type="pmcid">PMC7412170</pub-id><pub-id pub-id-type="pmid">32228108</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name><name name-style="western"><surname>Richards</surname><given-names>RL</given-names></name><name name-style="western"><surname>Moss</surname><given-names>J</given-names></name><name name-style="western"><surname>Alving</surname><given-names>LI</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Shiba</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen</article-title>. <source>Vaccine</source> (<year>1986</year>) <volume>4</volume>(<issue>3</issue>):<page-range>166&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0264-410x(86)90005-8</pub-id><pub-id pub-id-type="pmid">3532603</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>WI</given-names></name><name name-style="western"><surname>Cassatt</surname><given-names>DR</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Burke</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Woods</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wassef</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen</article-title>. <source>Vaccine</source> (<year>1995</year>) <volume>13</volume>(<issue>12</issue>):<page-range>1111&#8211;22</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0264-410x(94)00058-u</pub-id><pub-id pub-id-type="pmid">7491819</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memvanga</surname><given-names>PB</given-names></name><name name-style="western"><surname>Nkanga</surname><given-names>CI</given-names></name></person-group>. <article-title>Liposomes for malaria management: the evolution from 1980 to 2020</article-title>. <source>Malar. J</source> (<year>2021</year>) <volume>20</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>33</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12936-021-03858-0</pub-id><pub-id pub-id-type="pmid">34315484</pub-id><pub-id pub-id-type="pmcid">PMC8313885</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genito</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name><name name-style="western"><surname>Phares</surname><given-names>TW</given-names></name><name name-style="western"><surname>Kalle</surname><given-names>F</given-names></name><name name-style="western"><surname>Limbach</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Stefaniak</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Liposomes containing monophosphoryl lipid a and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>(<issue>31</issue>):<page-range>3865&#8211;74</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.070</pub-id><pub-id pub-id-type="pmid">28596090</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cawlfield</surname><given-names>A</given-names></name><name name-style="western"><surname>Genito</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bergmann-Leitner</surname><given-names>ES</given-names></name><name name-style="western"><surname>Bitzer</surname><given-names>AA</given-names></name><name name-style="western"><surname>Soto</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ)</article-title>. <source>Vaccine</source> (<year>2019</year>) <volume>37</volume>(<issue>29</issue>):<page-range>3793&#8211;803</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.059</pub-id><pub-id pub-id-type="pmid">31151801</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seth</surname><given-names>L</given-names></name><name name-style="western"><surname>Ferlez</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kaba</surname><given-names>SA</given-names></name><name name-style="western"><surname>Musser</surname><given-names>DM</given-names></name><name name-style="western"><surname>Emadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><etal/></person-group>. <article-title>Development of a self-assembling protein nanoparticle vaccine targeting plasmodium falciparum circumsporozoite protein delivered in three army liposome formulation adjuvants</article-title>. <source>Vaccine</source> (<year>2017</year>) <volume>35</volume>(<issue>41</issue>):<page-range>5448&#8211;54</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.040</pub-id><pub-id pub-id-type="pmid">28274638</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Paris</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title>. <source>N Engl J Med</source> (<year>2009</year>) <volume>361</volume>(<issue>23</issue>):<page-range>2209&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa0908492</pub-id><pub-id pub-id-type="pmid">19843557</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><name name-style="western"><surname>Jalah</surname><given-names>R</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Polonis</surname><given-names>VR</given-names></name><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name></person-group>. <article-title>Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid a with or without QS21</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>(<issue>42</issue>):<page-range>5578&#8211;87</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.001</pub-id><pub-id pub-id-type="pmid">26372857</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>Z</given-names></name><name name-style="western"><surname>Torres</surname><given-names>OB</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><name name-style="western"><surname>Lanar</surname><given-names>DE</given-names></name><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name></person-group>. <article-title>Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex</article-title>. <source>J Control Release</source> (<year>2018</year>) <volume>275</volume>:<page-range>12&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2018.02.006</pub-id><pub-id pub-id-type="pmcid">PMC5878139</pub-id><pub-id pub-id-type="pmid">29432824</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jobe</surname><given-names>O</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>DO</given-names></name><name name-style="western"><surname>Villar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>T</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>EH</given-names></name><etal/></person-group>. <article-title>Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating APOBEC3A</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>17</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-022-11230-8</pub-id><pub-id pub-id-type="pmid">35534646</pub-id><pub-id pub-id-type="pmcid">PMC9082986</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryz</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Que</surname><given-names>JU</given-names></name><name name-style="western"><surname>Gl&#252;ck</surname><given-names>R</given-names></name></person-group>. <article-title>A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans</article-title>. <source>Vaccine</source> (<year>1996</year>) <volume>14</volume>:<page-range>1381&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(96)00040-0</pub-id><pub-id pub-id-type="pmid">9004449</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mischler</surname><given-names>R</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>IC</given-names></name></person-group>. <article-title>Inflexal&#174; V a trivalent virosome subunit influenza vaccine: production</article-title>. <source>Vaccine</source> (<year>2002</year>) <volume>20</volume>:<page-range>B17&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(02)00512-1</pub-id><pub-id pub-id-type="pmid">12477413</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Kammer</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rasi</surname><given-names>S</given-names></name><name name-style="western"><surname>Westerfeld</surname><given-names>N</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R</given-names></name></person-group>. <article-title>Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations</article-title>. <source>Expert Rev Vaccines</source> (<year>2007</year>) <volume>6</volume>:<page-range>711&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14760584.6.5.711</pub-id><pub-id pub-id-type="pmid">17931152</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arkema</surname><given-names>A</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>P</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T</given-names></name></person-group>. <article-title>Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes</article-title>. <source>Vaccine</source> (<year>2000</year>) <volume>18</volume>:<page-range>1327&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(99)00404-1</pub-id><pub-id pub-id-type="pmid">10618529</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cusi</surname><given-names>MG</given-names></name></person-group>. <article-title>Applications of influenza virosomes as a delivery system</article-title>. <source>Hum Vaccines</source> (<year>2006</year>) <volume>2 1 7</volume>, <page-range>1&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.2.1.2494</pub-id><pub-id pub-id-type="pmid">17012895</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bungener</surname><given-names>L</given-names></name><name name-style="western"><surname>Serre</surname><given-names>K</given-names></name><name name-style="western"><surname>Bijl</surname><given-names>L</given-names></name><name name-style="western"><surname>Leserman</surname><given-names>L</given-names></name><name name-style="western"><surname>Wilschut</surname><given-names>J</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Virosome-mediated delivery of protein antigens to dendritic cells</article-title>. <source>Vaccine</source> (<year>2002</year>) <volume>20</volume>:<page-range>2287&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0264-410x(02)00103-2</pub-id><pub-id pub-id-type="pmid">12009284</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huckriede</surname><given-names>A</given-names></name><name name-style="western"><surname>Bungener</surname><given-names>L</given-names></name><name name-style="western"><surname>Stegmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Daemen</surname><given-names>T</given-names></name><name name-style="western"><surname>Medema</surname><given-names>J</given-names></name><name name-style="western"><surname>Palache</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>The virosome concept for influenza vaccines</article-title>. <source>Vaccine</source> (<year>2005</year>) <volume>23</volume>:<page-range>S26&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2005.04.026</pub-id><pub-id pub-id-type="pmid">16026906</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herzog</surname><given-names>C</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>K</given-names></name><name name-style="western"><surname>K&#252;nzi</surname><given-names>V</given-names></name><name name-style="western"><surname>K&#252;rsteiner</surname><given-names>O</given-names></name><name name-style="western"><surname>Mischler</surname><given-names>R</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Eleven years of inflexal V-a virosomaladjuvanted influenza vaccine</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<page-range>4381&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.029</pub-id><pub-id pub-id-type="pmid">19450630</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saroja</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lakshmi</surname><given-names>PK</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>S</given-names></name></person-group>. <article-title>Recent trends in vaccine delivery systems: a review</article-title>. <source>Int J Pharm Investig</source> (<year>2011</year>) <volume>1</volume>(<issue>2</issue>):<fpage>64</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.4103/2230-973x.82384</pub-id><pub-id pub-id-type="pmcid">PMC3465129</pub-id><pub-id pub-id-type="pmid">23071924</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burny</surname><given-names>W</given-names></name><name name-style="western"><surname>Callegaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><name name-style="western"><surname>Fissette</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Different adjuvantsinduce common innate pathways that are associated with enhanced adaptive responses against amodel antigen in humans</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>943</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00943</pub-id><pub-id pub-id-type="pmid">28855902</pub-id><pub-id pub-id-type="pmcid">PMC5557780</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>TF</given-names></name><name name-style="western"><surname>Horsmans</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Impact of adjuvants on CD4(+) T cell and b cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial</article-title>. <source>Clin Immunol</source> (<year>2016</year>) <volume>169</volume>:<fpage>16</fpage>&#8211;<lpage>27</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.clim.2016.05.007</pub-id><pub-id pub-id-type="pmid">27236001</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannini</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S</given-names></name><name name-style="western"><surname>Dessy</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Enhanced humoral and memory b cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<page-range>5937&#8211;49</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.005</pub-id><pub-id pub-id-type="pmid">16828940</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Giudice</surname><given-names>G</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group>. <article-title>Correlates of adjuvanticity: A review on adjuvants in licensed vaccines</article-title>. <source>Semin Immunol</source> (<year>2018</year>) <volume>39</volume>:<fpage>14</fpage>&#8211;<lpage>21</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismaili</surname><given-names>J</given-names></name><name name-style="western"><surname>Rennesson</surname><given-names>J</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>E</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name><name name-style="western"><surname>Vincart</surname><given-names>B</given-names></name><name name-style="western"><surname>Amraoui</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Monophosphoryl lipid a activates both human dendritic cells and T cells</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>168</volume>:<page-range>926 &#8211;932</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.168.2.926</pub-id><pub-id pub-id-type="pmid">11777991</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Becker</surname><given-names>G</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>V</given-names></name><name name-style="western"><surname>Pajak</surname><given-names>B</given-names></name><name name-style="western"><surname>Bruck</surname><given-names>C</given-names></name><name name-style="western"><surname>Francotte</surname><given-names>M</given-names></name><name name-style="western"><surname>Thiriart</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The adjuvant monophosphoryl lipid a increases the function of antigen-presenting cells</article-title>. <source>Int Immunol</source> (<year>2000</year>) <volume>12</volume>:<fpage>807</fpage>&#8211;<lpage>815</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1093/intimm/12.6.807</pub-id><pub-id pub-id-type="pmid">10837408</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>JT</given-names></name><name name-style="western"><surname>Cluff</surname><given-names>CW</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lacy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Persing</surname><given-names>DH</given-names></name><name name-style="western"><surname>Baldridge</surname><given-names>JR</given-names></name></person-group>. <article-title>Enhancement of antigen-specific immunity <italic toggle="yes">via</italic> the TLR4 ligands MPL adjuvant and Ribi.529</article-title>. <source>Expert Rev Vaccines</source> (<year>2003</year>) <volume>2</volume>:<page-range>219 &#8211;229</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/14760584.2.2.219</pub-id><pub-id pub-id-type="pmid">12899573</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldridge</surname><given-names>JR</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P</given-names></name><name name-style="western"><surname>Evans</surname><given-names>JT</given-names></name><name name-style="western"><surname>Cluff</surname><given-names>C</given-names></name><name name-style="western"><surname>Mossman</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents</article-title>. <source>Expert Opin Biol Ther</source> (<year>2004</year>) <volume>4</volume>:<page-range>1129&#8211;38</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1517/14712598.4.7.1129</pub-id><pub-id pub-id-type="pmid">15268679</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name></person-group>. <source>Vaccine adjuvants and delivery systems</source>. <publisher-name>John Wiley &amp; Sons</publisher-name> (<year>2007</year>) p. <page-range>151&#8211;3</page-range>.</mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>BS</given-names></name><name name-style="western"><surname>Chilton</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ward</surname><given-names>JR</given-names></name><name name-style="western"><surname>Evans</surname><given-names>JT</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>TC</given-names></name></person-group>. <article-title>The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells</article-title>. <source>J Leukoc. Biol</source> (<year>2005</year>) <volume>78</volume>:<page-range>1273&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1189/jlb.0305172</pub-id><pub-id pub-id-type="pmid">16204643</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoshi</surname><given-names>T</given-names></name></person-group>. <article-title>Modes of action for mucosal vaccine adjuvants</article-title>. <source>Viral Immunol</source> (<year>2017</year>) <volume>30</volume>:<page-range>463&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1089/vim.2017.0026</pub-id><pub-id pub-id-type="pmcid">PMC5512297</pub-id><pub-id pub-id-type="pmid">28436755</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name></person-group>. <article-title>Mucosal adjuvants: Opportunities and challenges</article-title>. <source>Hum.Vaccine Immunother</source> (<year>2016</year>) <volume>12</volume>:<page-range>2456&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/21645515.2016.1181236</pub-id><pub-id pub-id-type="pmcid">PMC5027714</pub-id><pub-id pub-id-type="pmid">27159278</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Lubben</surname><given-names>IM</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>JC</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G</given-names></name><name name-style="western"><surname>Junginger</surname><given-names>HE</given-names></name></person-group>. <article-title>Chitosan and its derivatives in mucosal drug and vaccine delivery</article-title>. <source>Eur J Pharm Sci</source> (<year>2001</year>) <volume>14</volume>:<page-range>201&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0928-0987(01)00172-5</pub-id><pub-id pub-id-type="pmid">11576824</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lycke</surname><given-names>N</given-names></name></person-group>. <article-title>Recent progress in mucosal vaccine development: potential and limitations</article-title>. <source>Nat Rev Immunol</source> (<year>2012</year>) <volume>12</volume>:<fpage>592</fpage>&#8211;<lpage>605</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nri3251</pub-id><pub-id pub-id-type="pmid">22828912</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedrud</surname><given-names>JG</given-names></name><name name-style="western"><surname>Bagheri</surname><given-names>N</given-names></name><name name-style="western"><surname>Sch&#246;n</surname><given-names>K</given-names></name><name name-style="western"><surname>Xin</surname><given-names>W</given-names></name><name name-style="western"><surname>Bergroth</surname><given-names>H</given-names></name><name name-style="western"><surname>Eliasson</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective <italic toggle="yes">Helicobacter pylori</italic> immunity</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>e83321</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0083321</pub-id><pub-id pub-id-type="pmid">24391754</pub-id><pub-id pub-id-type="pmcid">PMC3877028</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujihashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H</given-names></name></person-group>. <article-title>Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly</article-title>. <source>Exp Gerontol</source> (<year>2014</year>) <volume>54</volume>:<page-range>21&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.exger.2014.01.006</pub-id><pub-id pub-id-type="pmcid">PMC3989367</pub-id><pub-id pub-id-type="pmid">24440991</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;kvist Ottsj&#246;</surname><given-names>L</given-names></name><name name-style="western"><surname>Flach</surname><given-names>CF</given-names></name><name name-style="western"><surname>Clements</surname><given-names>J</given-names></name><name name-style="western"><surname>Holmgren</surname><given-names>J</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>S</given-names></name></person-group>. <article-title>A double mutant heat-labile toxin from <italic toggle="yes">Escherichia coli</italic>, LT (R192G/L211A), is an effective mucosal adjuvant for vaccination against helicobacter pylori infection</article-title>. <source>Infect Immun</source> (<year>2013</year>) <volume>81</volume>:<page-range>1532&#8211;40</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.01407-12</pub-id><pub-id pub-id-type="pmcid">PMC3647992</pub-id><pub-id pub-id-type="pmid">23439305</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallichan</surname><given-names>WS</given-names></name><name name-style="western"><surname>Woolstencroft</surname><given-names>RN</given-names></name><name name-style="western"><surname>Guarasci</surname><given-names>T</given-names></name><name name-style="western"><surname>McCluskie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HL</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>KL</given-names></name></person-group>. <article-title>Intranasal immunization with CpGoligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>:<page-range>3451&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.166.5.3451</pub-id><pub-id pub-id-type="pmid">11207303</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCluskie</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>HL</given-names></name></person-group>. <article-title>Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis b surface antigen with intranasal administration to mice</article-title>. <source>J Immunol</source> (<year>1998</year>) <volume>161</volume>:<page-range>4463&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.161.9.4463</pub-id><pub-id pub-id-type="pmid">9794366</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porgador</surname><given-names>A</given-names></name><name name-style="western"><surname>Staats</surname><given-names>HF</given-names></name><name name-style="western"><surname>Faiola</surname><given-names>B</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E</given-names></name><name name-style="western"><surname>Palker</surname><given-names>TJ</given-names></name></person-group>. <article-title>Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development <italic toggle="yes">in vivo</italic>
</article-title>. <source>J Immunol</source> (<year>1997</year>) <volume>158</volume>:<fpage>834</fpage>&#8211;<lpage>841</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.158.2.834</pub-id><pub-id pub-id-type="pmid">8993001</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>SY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WS</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kweon</surname><given-names>MN</given-names></name><name name-style="western"><surname>Kang</surname><given-names>CY</given-names></name></person-group>. <article-title>Alpha-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>175</volume>:<page-range>3309&#8211;17</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.175.5.3309</pub-id><pub-id pub-id-type="pmid">16116223</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name></person-group>. <article-title>The mucosal vaccine adjuvant LT(R192G/L211A) or dmLT</article-title>. <source>mSphere</source> (<year>2018</year>) <volume>3</volume>(<issue>4</issue>):<page-range>e00215&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/msphere.00215-18</pub-id><pub-id pub-id-type="pmcid">PMC6060342</pub-id><pub-id pub-id-type="pmid">30045966</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>LC</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name></person-group>. <article-title>Characterization of a mutant escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant</article-title>. <source>Clin Vaccine Immunol</source> (<year>2011</year>) <volume>18</volume>:<page-range>546&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/cvi.00538-10</pub-id><pub-id pub-id-type="pmcid">PMC3122563</pub-id><pub-id pub-id-type="pmid">21288994</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merritt</surname><given-names>EA</given-names></name><name name-style="western"><surname>Pronk</surname><given-names>SE</given-names></name><name name-style="western"><surname>Sixma</surname><given-names>TK</given-names></name><name name-style="western"><surname>Kalk</surname><given-names>KH</given-names></name><name name-style="western"><surname>van Zanten</surname><given-names>BA</given-names></name><name name-style="western"><surname>Hol</surname><given-names>WG</given-names></name></person-group>. <article-title>Structure of partially activated <italic toggle="yes">E. coli</italic> heat-labile enterotoxin (LT) at 2.6 a resolution</article-title>. <source>FEBS Lett</source> (<year>1994</year>) <volume>337</volume>:<fpage>88</fpage>&#8211;<lpage>92</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0014-5793(94)80635-7</pub-id><pub-id pub-id-type="pmid">8276119</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>BL</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Halperin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Langley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shamout</surname><given-names>Y</given-names></name><name name-style="western"><surname>Taddio</surname></name><etal/></person-group>. <article-title>A randomized control trial comparing immu- nogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<page-range>6287&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.08.006</pub-id><pub-id pub-id-type="pmid">22902784</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YC</given-names></name><name name-style="western"><surname>Jarrahian</surname><given-names>C</given-names></name><name name-style="western"><surname>Zehrung</surname><given-names>D</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S</given-names></name><name name-style="western"><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group>. <article-title>Delivery systems for intradermal vaccination</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2012</year>) <volume>351</volume>:<fpage>77</fpage>&#8211;<lpage>112</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/82_2011_123</pub-id><pub-id pub-id-type="pmid">21472533</pub-id><pub-id pub-id-type="pmcid">PMC3173582</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>J</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>R</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kaswekar</surname><given-names>AP</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Outbreak of viral hepatitis b in a rural community in India linked to inadequately sterilized needles and syringes</article-title>. <source>Bull World Health Organ</source> (<year>1998</year>) <volume>76</volume>:<page-range>93&#8211;8</page-range>.<pub-id pub-id-type="pmcid">PMC2305626</pub-id><pub-id pub-id-type="pmid">9615501</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aylward</surname><given-names>B</given-names></name><name name-style="western"><surname>Kane</surname><given-names>M</given-names></name><name name-style="western"><surname>McNair-Scott</surname><given-names>R</given-names></name><name name-style="western"><surname>Hu</surname><given-names>DH</given-names></name></person-group>. <article-title>Model-based estimates of the risk of human immunodeficiency virus and hepatitis b virus transmission through unsafe injections</article-title>. <source>. Int J Epidemiol</source> (<year>1995</year>) <volume>24</volume>:<page-range>446&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ije/24.2.446</pub-id><pub-id pub-id-type="pmid">7635609</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veldhoen</surname><given-names>M</given-names></name></person-group>. <article-title>Interleukin 17 is a chief orchestrator of immunity</article-title>. <source>Nat Immunol</source> (<year>2017</year>) <volume>18</volume>:<page-range>612&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.3742</pub-id><pub-id pub-id-type="pmid">28518156</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doreau</surname><given-names>A</given-names></name><name name-style="western"><surname>Belot</surname><given-names>A</given-names></name><name name-style="western"><surname>Bastid</surname><given-names>J</given-names></name><name name-style="western"><surname>Riche</surname><given-names>B</given-names></name><name name-style="western"><surname>Trescol-Biemont</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ranchin</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Interleukin 17 acts in synergy with b cell-activating factor to influence b cell biology and the pathophysiology of systemic lupus erythematosus</article-title>. <source>Nat Immunol</source> (<year>2009</year>) <volume>10</volume>:<page-range>778&#8211;85</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.1741</pub-id><pub-id pub-id-type="pmid">19483719</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitsdoerffer</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Korn</surname><given-names>T</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name><etal/></person-group>. <article-title>Proinflammatory T helper type 17 cells are effective b-cell helpers</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2010</year>) <volume>107</volume>:<page-range>14292&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1009234107</pub-id><pub-id pub-id-type="pmcid">PMC2922571</pub-id><pub-id pub-id-type="pmid">20660725</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ferrini</surname><given-names>ME</given-names></name><name name-style="western"><surname>Girtsman</surname><given-names>TA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>K</given-names></name></person-group>. <article-title>Antigen-specific treg regulate Th17-mediated lung neutrophilic inflammation. b-cell recruitment and polymeric IgA and IgM levels in the airways</article-title>. <source>Eur J Immunol</source> (<year>2009</year>) <volume>39</volume>:<page-range>3307&#8211;14</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.200939498</pub-id><pub-id pub-id-type="pmcid">PMC2849980</pub-id><pub-id pub-id-type="pmid">19830731</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaffar</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ferrini</surname><given-names>ME</given-names></name><name name-style="western"><surname>Herritt</surname><given-names>LA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>K</given-names></name></person-group>. <article-title>Cutting edge: lung mucosal Th17-mediated responses induce polymeric ig receptor expression by the airway epithelium and elevate secretory IgA levels</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>182</volume>:<page-range>4507&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0900237</pub-id><pub-id pub-id-type="pmcid">PMC2740792</pub-id><pub-id pub-id-type="pmid">19342622</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frederick</surname><given-names>DR</given-names></name><name name-style="western"><surname>Goggins</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>LM</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>LC</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>JB</given-names></name></person-group>. <article-title>Adjuvant selection regulates gut migration and phenotypic diversity of antigen specific CD4(+) T cells following parenteral immunization</article-title>. <source>Mucosal. Immunol</source> (<year>2018</year>) <volume>11</volume>:<page-range>549&#8211;61</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/mi.2017.70</pub-id><pub-id pub-id-type="pmcid">PMC6252260</pub-id><pub-id pub-id-type="pmid">28792004</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>DL</given-names></name><name name-style="western"><surname>Weldon</surname><given-names>WC</given-names></name><name name-style="western"><surname>Oberste</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name></person-group>. <article-title>The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vac- cine in a murine model</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<page-range>1909 &#8211;1915</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.02.069</pub-id><pub-id pub-id-type="pmid">25765967</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Novotny</surname><given-names>LA</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bakaletz</surname><given-names>LO</given-names></name></person-group>. <article-title>Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable haemophilus influenzae-induced otitis media after transcutaneous immunization</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<page-range>3417&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.033</pub-id><pub-id pub-id-type="pmcid">PMC3578125</pub-id><pub-id pub-id-type="pmid">23092856</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Picking</surname><given-names>WL</given-names></name><name name-style="western"><surname>Tzipori</surname><given-names>S</given-names></name></person-group>. <article-title>The immune response of two microbial antigens delivered intradermally, sublingually, or the combination thereof</article-title>. <source>Microbes Infect</source> (<year>2014</year>) <volume>16</volume>:<fpage>796</fpage>&#8211;<lpage>803</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.micinf.2014.07.013</pub-id><pub-id pub-id-type="pmid">25111827</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freytag</surname><given-names>LC</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name></person-group>. <article-title>Mucosal adjuvants</article-title>. <source>Vaccine</source> (<year>2005</year>) <volume>23</volume>:<page-range>1804&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.010</pub-id><pub-id pub-id-type="pmid">15734046</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name></person-group>. <article-title>Defending the mucosa: adjuvant and carrier formulations for mucosal immunity</article-title>. <source>Curr Opin Immunol</source> (<year>2011</year>) <volume>23</volume>:<fpage>414</fpage>&#8211;<lpage>420</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.coi.2011.03.009</pub-id><pub-id pub-id-type="pmid">21511452</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Voss</surname><given-names>TG</given-names></name><name name-style="western"><surname>C&#225;rdenas-Freytag</surname><given-names>L</given-names></name></person-group>. <article-title>Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model</article-title>. <source>J Virol</source> (<year>2010</year>) <volume>84</volume>:<page-range>2983&#8211;95</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jvi.01805-09</pub-id><pub-id pub-id-type="pmcid">PMC2826051</pub-id><pub-id pub-id-type="pmid">20053748</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anosova</surname><given-names>NG</given-names></name><name name-style="western"><surname>Chabot</surname><given-names>S</given-names></name><name name-style="western"><surname>Shreedhar</surname><given-names>V</given-names></name><name name-style="western"><surname>Borawski</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>BL</given-names></name><name name-style="western"><surname>Neutra</surname><given-names>MR</given-names></name></person-group>. <article-title>Cholera toxin, <italic toggle="yes">E. coli</italic> heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of peyer&#8217;s patches</article-title>. <source>Mucosal Immunol</source> (<year>2008</year>) <volume>1</volume>:<fpage>59</fpage>&#8211;<lpage>67</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/mi.2007.7</pub-id><pub-id pub-id-type="pmid">19079161</pub-id><pub-id pub-id-type="pmcid">PMC2614317</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagley</surname><given-names>KC</given-names></name><name name-style="western"><surname>Abdelwahab</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tuskan</surname><given-names>RG</given-names></name><name name-style="western"><surname>Fouts</surname><given-names>TR</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>GK</given-names></name></person-group>. <article-title>Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway</article-title>. <source>Infect Immun</source> (<year>2002</year>) <volume>70</volume>:<page-range>5533&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.70.10.5533-5539.2002</pub-id><pub-id pub-id-type="pmcid">PMC128358</pub-id><pub-id pub-id-type="pmid">12228279</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norton</surname><given-names>EB</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Freytag</surname><given-names>LC</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name></person-group>. <article-title>The a-subunit of escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA and Th17 responses to vaccine antigens</article-title>. <source>Infect Immun</source> (<year>2012</year>) <volume>80</volume>:<page-range>2426 &#8211;2435</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/iai.00181-12</pub-id><pub-id pub-id-type="pmcid">PMC3416479</pub-id><pub-id pub-id-type="pmid">22526674</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Forte</surname><given-names>S</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole- cell vaccine</article-title>. <source>Clin Vaccine Immunol</source> (<year>2010</year>) <volume>17</volume>:<page-range>1005&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/cvi.00036-10</pub-id><pub-id pub-id-type="pmcid">PMC2884428</pub-id><pub-id pub-id-type="pmid">20427625</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>S</given-names></name><name name-style="western"><surname>Clements</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kaim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lundgren</surname><given-names>A</given-names></name></person-group>. <article-title>The adjuvant double mutant escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens</article-title>. <source>PloS One</source> (<year>2012</year>) <volume>7</volume>:<elocation-id>e51718</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0051718</pub-id><pub-id pub-id-type="pmid">23284753</pub-id><pub-id pub-id-type="pmcid">PMC3527457</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Fonseca</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hand</surname><given-names>TW</given-names></name><name name-style="western"><surname>Han</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>MY</given-names></name><name name-style="western"><surname>Zaretsky</surname><given-names>AG</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Microbiota-dependent sequelae of acute infection compromise tissue-specific immunity</article-title>. <source>Cell</source> (<year>2015</year>) <volume>163</volume>:<page-range>354 &#8211;366</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2015.08.030</pub-id><pub-id pub-id-type="pmcid">PMC4826740</pub-id><pub-id pub-id-type="pmid">26451485</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brereton</surname><given-names>CF</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>CE</given-names></name><name name-style="western"><surname>Ross</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">Escherichia coli</italic> heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>:<page-range>5896&#8211;906</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1003789</pub-id><pub-id pub-id-type="pmid">21490151</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosaheb</surname><given-names>MM</given-names></name><name name-style="western"><surname>Reiser</surname><given-names>ML</given-names></name><name name-style="western"><surname>Wetzler</surname><given-names>LM</given-names></name></person-group>. <article-title>Toll-like receptor ligand-based vaccine adjuvants require intact MyD88 signaling in antigen-presenting cells for germinal center formation and antibody production</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>225</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.00225</pub-id><pub-id pub-id-type="pmid">28316602</pub-id><pub-id pub-id-type="pmcid">PMC5334362</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shetab Boushehri</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lamprecht</surname><given-names>A</given-names></name></person-group>. <article-title>TLR4-based immunotherapeutics in cancer: a review of the achievements and shortcomings</article-title>. <source>Mol Pharm</source> (<year>2018</year>) <volume>15</volume>(<issue>11</issue>):<page-range>4777&#8211;800</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00691</pub-id><pub-id pub-id-type="pmid">30226786</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Poncet</surname><given-names>D</given-names></name><name name-style="western"><surname>Seydoux</surname><given-names>E</given-names></name><name name-style="western"><surname>Rintala</surname><given-names>ND</given-names></name><name name-style="western"><surname>Maciel</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine</article-title>. <source>NPG Vaccines</source> (<year>2019</year>) <volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>8</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-019-0116-6</pub-id><pub-id pub-id-type="pmcid">PMC6538625</pub-id><pub-id pub-id-type="pmid">31149350</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>SK</given-names></name><name name-style="western"><surname>Heo</surname><given-names>YK</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ham</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yum</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>BC</given-names></name><etal/></person-group>. <article-title>COVID-19 subunit vaccine with a combination of TLR1/2 and TLR3 agonists induces robust and protective <italic toggle="yes">immunity</italic>
</article-title>. <source>Vaccines</source> (<year>2021</year>) <volume>9</volume>(<issue>9</issue>):<elocation-id>957</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/vaccines9090957</pub-id><pub-id pub-id-type="pmid">34579194</pub-id><pub-id pub-id-type="pmcid">PMC8473206</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name><name name-style="western"><surname>Ward</surname><given-names>RW</given-names></name></person-group>. <article-title>Mucosal vaccines&#8211;fortifying the frontiers</article-title>. <source>Nat Rev Immunol</source> (<year>2022</year>) <volume>22</volume>(<issue>4</issue>):<page-range>236&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41577-021-00583-2</pub-id><pub-id pub-id-type="pmcid">PMC8312369</pub-id><pub-id pub-id-type="pmid">34312520</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>WE</given-names></name></person-group>. <article-title>Bridging innate and adaptive immunity</article-title>. <source>Cell</source> (<year>2011</year>) <volume>147</volume>:<page-range>1212&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2011.11.036</pub-id><pub-id pub-id-type="pmid">22153065</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinon</surname><given-names>F</given-names></name><name name-style="western"><surname>Mayor</surname><given-names>A</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J</given-names></name></person-group>. <article-title>The inflammasomes: guardians of the body</article-title>. <source>Annu Rev Immunol</source> (<year>2009</year>) <volume>27</volume>:<page-range>229&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132715</pub-id><pub-id pub-id-type="pmid">19302040</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A</given-names></name><name name-style="western"><surname>Seder</surname><given-names>RA</given-names></name></person-group>. <article-title>Vaccine adjuvants: putting innate immunity to work</article-title>. <source>Immunity</source> (<year>2010</year>) <volume>33</volume>:<fpage>492</fpage>&#8211;<lpage>503</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>DM</given-names></name></person-group>. <article-title>Use of novel adjuvants and delivery systems to improve the humoral and cellular immune response to malaria vaccine candidate antigens</article-title>. <source>Vaccine</source> (<year>1993</year>) <volume>11</volume>:<page-range>591&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0264-410x(93)90239-t</pub-id><pub-id pub-id-type="pmid">8488718</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N</given-names></name><name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></name></person-group>. <article-title>Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems</article-title>. <source>Expert Rev Vacc</source> (<year>2011</year>) <volume>10</volume>:<page-range>471&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1586/erv.11.29</pub-id><pub-id pub-id-type="pmid">21506645</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>IF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>AJ</given-names></name><name name-style="western"><surname>To</surname><given-names>KK</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TL</given-names></name><etal/></person-group>. <article-title>Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial</article-title>. <source>Lancet Infect Dis</source> (<year>2016</year>) <volume>16</volume>(<issue>2</issue>):<page-range>209&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(15)00354-0</pub-id><pub-id pub-id-type="pmid">26559482</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan D</surname><given-names>T</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>LR</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group>. <article-title>Towards an evidence based approach for the development of adjuvanted vaccines</article-title>. <source>Curr Opin Immunol</source> (<year>2017</year>) <volume>47</volume>:<fpage>93</fpage>&#8211;<lpage>102</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.coi.2017.07.010</pub-id><pub-id pub-id-type="pmid">28755542</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>GK</given-names></name><name name-style="western"><surname>H&#246;schler</surname><given-names>K</given-names></name><name name-style="western"><surname>Solbak</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bredholt</surname><given-names>G</given-names></name><name name-style="western"><surname>Pathirana</surname><given-names>RD</given-names></name><name name-style="western"><surname>Afsar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>(<issue>35</issue>):<page-range>4550&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.009</pub-id><pub-id pub-id-type="pmid">24950357</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>TA</given-names></name><name name-style="western"><surname>Penn-Nicholson</surname><given-names>A</given-names></name><name name-style="western"><surname>Luabeya</surname><given-names>AK</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A</given-names></name><name name-style="western"><surname>Du Plessis</surname><given-names>N</given-names></name><name name-style="western"><surname>Loxton</surname><given-names>AG</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of the adjunct therapeutic vaccine ID93&#8200;+&#8200;GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial</article-title>. <source>Lancet Respir Med</source> (<year>2021</year>) <volume>9</volume>(<issue>4</issue>):<page-range>373&#8211;86</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30319-2</pub-id><pub-id pub-id-type="pmid">33306991</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenum</surname><given-names>S</given-names></name><name name-style="western"><surname>Tonby</surname><given-names>K</given-names></name><name name-style="western"><surname>Rueegg</surname><given-names>CS</given-names></name><name name-style="western"><surname>R&#252;hwald</surname><given-names>M</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>MP</given-names></name><name name-style="western"><surname>Bang</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>(<issue>1</issue>):<fpage>6774</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-27029-6</pub-id><pub-id pub-id-type="pmid">34811370</pub-id><pub-id pub-id-type="pmcid">PMC8608791</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pleguezuelos</surname><given-names>O</given-names></name><name name-style="western"><surname>Dille</surname><given-names>J</given-names></name><name name-style="western"><surname>de Groen</surname><given-names>S</given-names></name><name name-style="western"><surname>Oftung</surname><given-names>F</given-names></name><name name-style="western"><surname>Niesters</surname><given-names>HG</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Immunogenicity, safety, and efficacy of a standalone universal influenza vaccine, FLU-v, in healthy adults: A randomized clinical trial</article-title>. <source>Ann Intern Med</source> (<year>2020</year>) <volume>172</volume>(<issue>7</issue>):<page-range>453&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.7326/M19-0735</pub-id><pub-id pub-id-type="pmid">32150750</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>JX</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>GY</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hong</surname><given-names>YR</given-names></name><etal/></person-group>. <article-title>Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases</article-title>. <source>Pharmaceutics</source> (<year>2022</year>) <volume>14</volume>(<issue>2</issue>):<elocation-id>423</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/pharmaceutics14020423</pub-id><pub-id pub-id-type="pmid">35214155</pub-id><pub-id pub-id-type="pmcid">PMC8878135</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overton</surname><given-names>ET</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>PA</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>P</given-names></name><name name-style="western"><surname>Carter</surname><given-names>WA</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>J</given-names></name><name name-style="western"><surname>Young</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans</article-title>. <source>Vaccine</source> (<year>2014</year>) <volume>32</volume>(<issue>42</issue>):<page-range>5490&#8211;5</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.078</pub-id><pub-id pub-id-type="pmid">25128802</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>SL</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C</given-names></name></person-group>. <article-title>Future prospects for new vaccines against sexually transmitted infections</article-title>. <source>Curr Opin Infect Dis</source> (<year>2017</year>) <volume>30</volume>(<issue>1</issue>):<fpage>77</fpage>&#8211;<lpage>86</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/QCO.0000000000000343</pub-id><pub-id pub-id-type="pmid">27922851</pub-id><pub-id pub-id-type="pmcid">PMC5325242</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kester</surname><given-names>KE</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>JF</given-names></name><name name-style="western"><surname>Ofori-Anyinam</surname><given-names>O</given-names></name><name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></name><name name-style="western"><surname>Krzych</surname><given-names>U</given-names></name><name name-style="western"><surname>Moris</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria- naive adults: safety, efficacy, and immunologic associates of protection</article-title>. <source>J Infect Dis</source> (<year>2009</year>) <volume>200</volume>:<page-range>337&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1086/600120</pub-id><pub-id pub-id-type="pmid">19569965</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallory</surname><given-names>RM</given-names></name><name name-style="western"><surname>Formica</surname><given-names>N</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>B</given-names></name><name name-style="western"><surname>Marcheschi</surname><given-names>A</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A secondary analysis of a randomised, placebo-controlled, phase 2 trial</article-title>. <source>Lancet Infect Dis</source> (<year>2022</year>) <volume>22</volume>(<issue>11</issue>):<page-range>1565&#8211;76</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00420-0</pub-id><pub-id pub-id-type="pmcid">PMC9365313</pub-id><pub-id pub-id-type="pmid">35963274</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>LA</given-names></name><name name-style="western"><surname>Malyala</surname><given-names>P</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Vaccine adjuvant formulations: a pharmaceutical perspective</article-title>. <source>Semin Immunol</source> (<year>2013</year>) <volume>25</volume>:<page-range>130&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.smim.2013.05.007</pub-id><pub-id pub-id-type="pmid">23850011</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabro</surname><given-names>S</given-names></name><name name-style="western"><surname>Tortoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>BC</given-names></name><name name-style="western"><surname>Pacitto</surname><given-names>A</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><etal/></person-group>. <article-title>Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<fpage>1812</fpage>&#8211;<lpage>1823</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.090</pub-id><pub-id pub-id-type="pmid">21215831</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabro</surname><given-names>S</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E</given-names></name><name name-style="western"><surname>Pezzotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Taccone</surname><given-names>M</given-names></name><name name-style="western"><surname>Muzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<page-range>3363&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.007</pub-id><pub-id pub-id-type="pmid">23684834</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S</given-names></name><name name-style="western"><surname>Fierens</surname><given-names>K</given-names></name><name name-style="western"><surname>Fochesato</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>193</volume>:<page-range>1920&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1400948</pub-id><pub-id pub-id-type="pmid">25024381</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duewell</surname><given-names>P</given-names></name><name name-style="western"><surname>Kisser</surname><given-names>U</given-names></name><name name-style="western"><surname>Heckelsmiller</surname><given-names>K</given-names></name><name name-style="western"><surname>Hoves</surname><given-names>S</given-names></name><name name-style="western"><surname>Stoitzner</surname><given-names>P</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>:<fpage>55</fpage>&#8211;<lpage>63</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1004114</pub-id><pub-id pub-id-type="pmid">21613613</pub-id><pub-id pub-id-type="pmcid">PMC4285562</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dendouga</surname><given-names>N</given-names></name><name name-style="western"><surname>Fochesato</surname><given-names>M</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L</given-names></name><name name-style="western"><surname>Mossman</surname><given-names>S</given-names></name><name name-style="western"><surname>Giannini</surname><given-names>SL</given-names></name></person-group>. <article-title>Cell-mediated immune responses to a varicella-zoster virus glycoprotein e vaccine using both a TLR agonist and QS21 in mice</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<page-range>3126&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.01.088</pub-id><pub-id pub-id-type="pmid">22326899</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coccia</surname><given-names>M</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Herv&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Chalon</surname><given-names>A</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN-&#947; response promoting vaccine immunogenicity</article-title>. <source>NPJ Vaccines</source> (<year>2017</year>) <volume>2</volume>:<fpage>25</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41541-017-0027-3</pub-id><pub-id pub-id-type="pmid">29263880</pub-id><pub-id pub-id-type="pmcid">PMC5627273</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laup&#232;ze</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></name><name name-style="western"><surname>Hergli</surname><given-names>N</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N</given-names></name></person-group>. <article-title>Adjuvant system AS01: helping to overcome the challenges of modern vaccines</article-title>. <source>Expert Rev Vaccines</source> (<year>2017</year>) <volume>1</volume>:<fpage>55</fpage>&#8211;<lpage>63</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id><pub-id pub-id-type="pmid">27448771</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detienne</surname><given-names>S</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Central role of CD169<sup>+</sup> lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>39475</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep39475</pub-id><pub-id pub-id-type="pmid">27996000</pub-id><pub-id pub-id-type="pmcid">PMC5172233</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kool</surname><given-names>M</given-names></name><name name-style="western"><surname>P&#233;trilli</surname><given-names>V</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>T</given-names></name><name name-style="western"><surname>Rolaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H</given-names></name><name name-style="western"><surname>Van Nimwegen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>:<page-range>3755&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.181.6.3755</pub-id><pub-id pub-id-type="pmid">18768827</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>NS</given-names></name><name name-style="western"><surname>Duewell</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marsters</surname><given-names>S</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>:<page-range>3259&#8211;68</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1302011</pub-id><pub-id pub-id-type="pmid">24610009</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welsby</surname><given-names>I</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S</given-names></name><name name-style="western"><surname>N&#8217;Kuli</surname><given-names>F</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>663</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2016.00663</pub-id><pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caproni</surname><given-names>E</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>Muzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mosca</surname><given-names>F</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<page-range>3088&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1101764</pub-id><pub-id pub-id-type="pmid">22351935</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cauwelaert</surname><given-names>ND</given-names></name><name name-style="western"><surname>Desbien</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>TE</given-names></name><name name-style="western"><surname>Pine</surname><given-names>SO</given-names></name><name name-style="western"><surname>Reed</surname><given-names>SG</given-names></name><name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name><etal/></person-group>. <article-title>TLR4 agonist vaccine adjuvant, GLA-SE, requires anonical and atypical mechanisms of action for TH1 anduction</article-title>. <source>PloS One</source> (<year>2016</year>) <volume>. 11</volume>:<elocation-id>e0146372</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0146372</pub-id><pub-id pub-id-type="pmid">26731269</pub-id><pub-id pub-id-type="pmcid">PMC4701231</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>AT</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>MP</given-names></name><name name-style="western"><surname>Rochat</surname><given-names>AF</given-names></name><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><name name-style="western"><surname>Lingnau</surname><given-names>K</given-names></name><name name-style="western"><surname>von Gabain</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells</article-title>. <source>Eur J Immunol</source> (<year>2008</year>) <volume>38</volume>:<page-range>1247&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/eji.200737889</pub-id><pub-id pub-id-type="pmid">18412160</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>AT</given-names></name><name name-style="western"><surname>Rochat</surname><given-names>AF</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>PH</given-names></name><etal/></person-group>. <article-title>A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells</article-title>. <source>PloS One</source> (<year>2009</year>) <volume>4</volume>:<elocation-id>e5771</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0005771</pub-id><pub-id pub-id-type="pmid">19492047</pub-id><pub-id pub-id-type="pmcid">PMC2685976</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>AT</given-names></name><name name-style="western"><surname>Mastelic</surname><given-names>B</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>D</given-names></name><name name-style="western"><surname>Rochat</surname><given-names>AF</given-names></name><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pinschewer</surname><given-names>DD</given-names></name><etal/></person-group>. <article-title>Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<page-range>4828&#8211;37</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1103183</pub-id><pub-id pub-id-type="pmid">22504654</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werninghaus</surname><given-names>K</given-names></name><name name-style="western"><surname>Babiak</surname><given-names>A</given-names></name><name name-style="western"><surname>Gro&#223;</surname><given-names>O</given-names></name><name name-style="western"><surname>H&#246;lscher</surname><given-names>C</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>H</given-names></name><name name-style="western"><surname>Agger</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Adjuvanticity of a synthetic cord factor analogue for subunit mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation</article-title>. <source>J Exp Med</source> (<year>2009</year>) <volume>206</volume>:<fpage>89</fpage>&#8211;<lpage>97</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1084/jem.20081445</pub-id><pub-id pub-id-type="pmid">19139169</pub-id><pub-id pub-id-type="pmcid">PMC2626670</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazmin</surname><given-names>D</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EK</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R</given-names></name><name name-style="western"><surname>Van Den Berg</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Systems analysis of protective immune responses to RTS,S malaria vaccination in humans</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2017</year>) <volume>114</volume>:<page-range>2425&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.1621489114</pub-id><pub-id pub-id-type="pmcid">PMC5338562</pub-id><pub-id pub-id-type="pmid">28193898</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobolev</surname><given-names>O</given-names></name><name name-style="western"><surname>Binda</surname><given-names>E</given-names></name><name name-style="western"><surname>O'farrell</surname><given-names>S</given-names></name><name name-style="western"><surname>Lorenc</surname><given-names>A</given-names></name><name name-style="western"><surname>Pradines</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events</article-title>. <source>Nat Immunol</source> (<year>2016</year>) <volume>17</volume>:<page-range>204&#8211;13</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.3328</pub-id><pub-id pub-id-type="pmcid">PMC6485475</pub-id><pub-id pub-id-type="pmid">26726811</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desbien</surname><given-names>AL</given-names></name><name name-style="western"><surname>Dubois Cauwelaert</surname><given-names>N</given-names></name><name name-style="western"><surname>Reed</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bailor</surname><given-names>HR</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>IL-18 and subcapsular lymph node macrophages are essential for enhanced b cell responses with TLR4 agonist adjuvants</article-title>. <source>J Immunol</source> (<year>2016</year>) <volume>197</volume>:<page-range>4351&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1600993</pub-id><pub-id pub-id-type="pmcid">PMC5123812</pub-id><pub-id pub-id-type="pmid">27794001</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentebibel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Khurana</surname><given-names>S</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>N</given-names></name><name name-style="western"><surname>Kurup</surname><given-names>P</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>C</given-names></name><name name-style="western"><surname>Obermoser</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>26494</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep26494</pub-id><pub-id pub-id-type="pmid">27231124</pub-id><pub-id pub-id-type="pmcid">PMC4882544</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazilleau</surname><given-names>N</given-names></name><name name-style="western"><surname>McHeyzer-Williams</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>H</given-names></name><name name-style="western"><surname>McHeyzer-Williams</surname><given-names>MG</given-names></name></person-group>. <article-title>The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding</article-title>. <source>Nat Immunol</source> (<year>2009</year>) <volume>10</volume>:<page-range>375&#8211;84</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ni.1704</pub-id><pub-id pub-id-type="pmcid">PMC2712297</pub-id><pub-id pub-id-type="pmid">19252493</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>EP</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>DN</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M</given-names></name><name name-style="western"><surname>Browne</surname><given-names>D</given-names></name><name name-style="western"><surname>Burns</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of NVX-CoV2373 covid-19 vaccine</article-title>. <source>N Engl J Med</source> (<year>2021</year>) <volume>385</volume>(<issue>13</issue>):<page-range>1172&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2107659</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id><pub-id pub-id-type="pmid">34192426</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacks</surname><given-names>HS</given-names></name></person-group>. <article-title>The novavax vaccine had 90% efficacy against COVID-19&#8805; 7 d after the second dose</article-title>. <source>Ann Internal Med</source> (<year>2021</year>) <volume>174</volume>(<issue>11</issue>):<fpage>JC124</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.7326/acpj202111160-124</pub-id><pub-id pub-id-type="pmid">34724399</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>383</volume>(<issue>24</issue>):<page-range>2320&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/nejmoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id><pub-id pub-id-type="pmid">32877576</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Datoo</surname><given-names>MS</given-names></name><name name-style="western"><surname>Natama</surname><given-names>MH</given-names></name><name name-style="western"><surname>Som&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Traor&#233;</surname><given-names>O</given-names></name><name name-style="western"><surname>Rouamba</surname><given-names>T</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-m, with seasonal administration to children in Burkina Faso: a randomised controlled trial</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>397</volume>(<issue>10287</issue>):<page-range>1809&#8211;18</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(21)00943-0</pub-id><pub-id pub-id-type="pmcid">PMC8121760</pub-id><pub-id pub-id-type="pmid">33964223</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lilja</surname><given-names>L</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L</given-names></name></person-group>. <article-title>Immune enhancing properties of the novel matrix-m&#8482; adjuvant leads to potentiated immune responses to an influenza vaccine in mice</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>(<issue>13</issue>):<page-range>1725&#8211;33</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.01.039</pub-id><pub-id pub-id-type="pmid">23384754</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>BH</given-names></name><name name-style="western"><surname>Munroe</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Leombruno</surname><given-names>D</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses</article-title>. <source>J Immunol</source> (<year>1992</year>) <volume>148</volume>(<issue>8</issue>):<page-range>2357&#8211;62</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.148.8.2357</pub-id><pub-id pub-id-type="pmid">1373166</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>BH</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>CI</given-names></name><name name-style="western"><surname>Seals</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>CR</given-names></name><name name-style="western"><surname>Recchia</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine</article-title>. <source>J Immunol</source> (<year>1992</year>) <volume>148</volume>(<issue>5</issue>):<page-range>1519&#8211;25</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.148.5.1519</pub-id><pub-id pub-id-type="pmid">1538134</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosca</surname><given-names>F</given-names></name><name name-style="western"><surname>Tritto</surname><given-names>E</given-names></name><name name-style="western"><surname>Muzzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Monaci</surname><given-names>E</given-names></name><name name-style="western"><surname>Bagnoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Iavarone</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Molecular and cellular signatures of human vaccine adjuvants</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2008</year>) <volume>105</volume>:<page-range>10501&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0804699105</pub-id><pub-id pub-id-type="pmcid">PMC2483233</pub-id><pub-id pub-id-type="pmid">18650390</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olafsdottir</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lindqvist</surname><given-names>M</given-names></name><name name-style="western"><surname>Nookaew</surname><given-names>I</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Maertzdorf</surname><given-names>J</given-names></name><name name-style="western"><surname>Persson</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Comparative systems analyses reveal molecular signatures of clinically tested vaccine adjuvants</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<elocation-id>39097</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep39097</pub-id><pub-id pub-id-type="pmid">27958370</pub-id><pub-id pub-id-type="pmcid">PMC5153655</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Medaglini</surname><given-names>D</given-names></name></person-group>. <article-title>ADITEC: joining forces for next-generation vaccines</article-title>. <source>Sci Transl Med</source> (<year>2012</year>) <volume>4</volume>:<fpage>128cm4</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3003826</pub-id><pub-id pub-id-type="pmid">22491948</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwissa</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Oluoch</surname><given-names>H</given-names></name></person-group>. <article-title>Pulendran B.Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>:<page-range>2044&#8211;55</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1182/blood-2011-10-388579</pub-id><pub-id pub-id-type="pmcid">PMC3311246</pub-id><pub-id pub-id-type="pmid">22246032</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaccari</surname><given-names>M</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>SN</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S</given-names></name><name name-style="western"><surname>Schifanella</surname><given-names>L</given-names></name><name name-style="western"><surname>Liyanage</surname><given-names>NP</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition</article-title>. <source>Nat Med</source> (<year>2016</year>) <volume>7</volume>:<page-range>762&#8211;70</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nm.4105</pub-id><pub-id pub-id-type="pmcid">PMC5916782</pub-id><pub-id pub-id-type="pmid">27239761</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>H</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I</given-names></name><name name-style="western"><surname>Lane</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Polyfunctional fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines</article-title>. <source>Sci Transl Med</source> (<year>2014</year>) <volume>6</volume>:<fpage>228ra38</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/scitranslmed.3007736</pub-id><pub-id pub-id-type="pmid">24648341</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name><name name-style="western"><surname>Schoen</surname><given-names>M</given-names></name><name name-style="western"><surname>Dunphy</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology</article-title>. <source>Cell</source> (<year>2015</year>) <volume>163</volume>:<page-range>988&#8211;98</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2015.10.027</pub-id><pub-id pub-id-type="pmcid">PMC5490491</pub-id><pub-id pub-id-type="pmid">26544943</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Della Cioppa</surname><given-names>G</given-names></name><name name-style="western"><surname>Jonsdottir</surname><given-names>I</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D</given-names></name></person-group>. <article-title>Challenges in early clinical development of adjuvanted vaccines</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>(<issue>Suppl 2</issue>):<page-range>B47&#8211;51</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.02.031</pub-id><pub-id pub-id-type="pmid">26022568</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>LA</given-names></name><name name-style="western"><surname>O'Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Designing and building the next generation of improved vaccine adjuvants</article-title>. <source>J Control Release</source> (<year>2014</year>) <volume>190</volume>:<page-range>563&#8211;79</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jconrel.2014.06.027</pub-id><pub-id pub-id-type="pmid">24998942</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakaya</surname><given-names>HI</given-names></name></person-group>. <article-title>Pulendran B.Vaccinology in the era of high- throughput biology</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2015</year>) <volume>370</volume>:<fpage>20140146</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1098/rstb.2014.0146</pub-id><pub-id pub-id-type="pmid">25964458</pub-id><pub-id pub-id-type="pmcid">PMC4527391</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olafsdottir</surname><given-names>T</given-names></name><name name-style="western"><surname>Lindqvist</surname><given-names>M</given-names></name><name name-style="western"><surname>Harandi</surname><given-names>AM</given-names></name></person-group>. <article-title>Molecular signatures of vaccine adjuvants</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<page-range>5302&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.099</pub-id><pub-id pub-id-type="pmid">25989447</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panilaitis</surname><given-names>B</given-names></name><name name-style="western"><surname>Johri</surname><given-names>A</given-names></name><name name-style="western"><surname>Blank</surname><given-names>W</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>D</given-names></name><name name-style="western"><surname>Fuhrman</surname><given-names>J</given-names></name></person-group>. <article-title>Adjuvant activity of emulsan, a secreted lipopolysaccharide from</article-title>. <source>Clin Diagn. Lab Immunol</source> (<year>2002</year>) <volume>9</volume>(<issue>6</issue>):<page-range>1240&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/cdli.9.6.1240-1247.2002</pub-id><pub-id pub-id-type="pmcid">PMC130088</pub-id><pub-id pub-id-type="pmid">12414756</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>I</given-names></name><name name-style="western"><surname>Garg</surname><given-names>R</given-names></name><name name-style="western"><surname>van Drunen Little-van den Hurk</surname><given-names>S</given-names></name></person-group>. <article-title>Selection of adjuvants for vaccine targeting specific pathogens</article-title>. <source>Expert Rev Vaccines</source> (<year>2019</year>) <volume>18</volume>(<issue>5</issue>):<page-range>505&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/14760584.2019.1604231</pub-id><pub-id pub-id-type="pmcid">PMC7103699</pub-id><pub-id pub-id-type="pmid">31009255</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardani</surname><given-names>K</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A</given-names></name></person-group>. <article-title>Shahbazi S.Prime-boost vaccine strategy against viral infections: Mechanisms and benefits</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<page-range>413&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.062</pub-id><pub-id pub-id-type="pmid">26691569</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omosa-Manyonyi</surname><given-names>G</given-names></name><name name-style="western"><surname>Mpendo</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruzagira</surname><given-names>E</given-names></name><name name-style="western"><surname>Kilembe</surname><given-names>W</given-names></name><name name-style="western"><surname>Chomba</surname><given-names>E</given-names></name><name name-style="western"><surname>Roman</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 gag-Pol-Nef fusion protein and adenovirus 35 gag-RT-Int-Nef vaccine in healthy HIV-uninfected African adults</article-title>. <source>PloS One</source> (<year>2015</year>) <volume>. 10</volume>:<elocation-id>e0125954</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0125954</pub-id><pub-id pub-id-type="pmid">25961283</pub-id><pub-id pub-id-type="pmcid">PMC4427332</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhtar</surname><given-names>M</given-names></name><name name-style="western"><surname>Nizam</surname><given-names>NN</given-names></name><name name-style="western"><surname>Basher</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>L</given-names></name><name name-style="western"><surname>Akter</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhuiyan</surname><given-names>TR</given-names></name><etal/></person-group>. <article-title>dmLT adjuvant enhances cytokine responses to T cell stimuli, whole cell vaccine antigens and lipopolysaccharide in both adults and infants</article-title>. <source>Front Immunol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>654872</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.654872</pub-id><pub-id pub-id-type="pmid">34054818</pub-id><pub-id pub-id-type="pmcid">PMC8160295</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G</given-names></name><name name-style="western"><surname>Phogat</surname><given-names>S</given-names></name><name name-style="western"><surname>Pecetta</surname><given-names>S</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M</given-names></name></person-group>. <article-title>Vaccinology in the post&#8211;COVID-19 era</article-title>. <source>Proc Natl Acad Sci U.S.A</source> (<year>2021</year>) <volume>118</volume>(<issue>3</issue>):<elocation-id>e2020368118</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2020368118</pub-id><pub-id pub-id-type="pmid">33431690</pub-id><pub-id pub-id-type="pmcid">PMC7826410</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>